Document:

<PAGE>
                                                                  Exhibit 10.20

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS
([*]), HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED

                                LICENSE AGREEMENT

         THIS AGREEMENT, effective as of March 15, 2002 ("EFFECTIVE DATE"), is
made by and between THE GENERAL HOSPITAL CORPORATION, a not-for-profit
corporation doing business as Massachusetts General Hospital, having a place of
business at Fruit Street, Boston, Massachusetts 02114 ("GENERAL"), and VIACELL
ENDOCRINE SCIENCE, INC., a subsidiary of ViaCell, Inc., having offices at 131
Clarendon Street, Boston, Massachusetts 02116 ("VIACELL").

         WHEREAS, under research programs funded by the Howard Hughes Medical
Institute ("HHMI"), GENERAL and the U.S. Government, HHMI and GENERAL, through
research conducted by Dr. Joel Habener, Dr. Denise Faustman and their
colleagues, having developed inventions pertaining to pancreatic stem cells for
treatment of diabetes;

         WHEREAS, GENERAL has filed U.S. and foreign patent applications
covering said inventions;

         WHEREAS, pursuant to the Patent and Intellectual Property Agreement
between HHMI and GENERAL dated November 16, 1987, all of Dr. Joel Habener's and
other HHMI employees' rights, title and interest in said applications have been
assigned by HHMI to GENERAL;

         WHEREAS, all of Dr. Denise Faustman's rights, title and interest in
said applications have been assigned to GENERAL;

         WHEREAS, GENERAL represents to the best of its knowledge and belief
that it is the owner of all rights, title and interest in said patent
applications and has the right and ability to grant the licenses hereinafter
described;

         WHEREAS, as centers for research and education, GENERAL and HHMI are
interested in licensing said patent applications and thus benefiting the public,
and in facilitating the dissemination of the results of research in the form of
useful products, but are without capacity to commercially develop, manufacture,
and distribute any such product; and

         WHEREAS, VIACELL having such capacity, desires to commercially develop,
manufacture, use and distribute such products throughout the world;

         NOW THEREFORE, in consideration of the premises and of the faithful
performance of the covenants herein contained, the parties hereto agree as
follows:

                                 1. DEFINITIONS

         1.1 The term "ACCOUNTING PERIOD" shall mean each six-month period
ending June 30 and December 31.

         1.2 The term "AFFILIATE" with respect to VIACELL shall mean any
corporation or other legal entity controlling, controlled by or under common
control with VIACELL. The term

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
"AFFILIATE" with respect to GENERAL shall mean any company controlling,
controlled by, or under common control with GENERAL. The term "control" means
possession, direct or indirect, of the powers to direct or cause the direction
of the management and policies of an entity, whether through the ownership of
voting securities, by contract or otherwise.

         1.3 The term "FIRST COMMERCIAL SALE" shall mean in each country the
first sale of any PRODUCT by VIACELL, its AFFILIATES or SUBLICENSEES.

         1.4 The term "LICENSE FIELD" shall mean the diagnosis, treatment or
prevention of human and animal diseases and conditions.

         1.5 The term "NET SALE PRICE" shall mean the GROSS SALES PRICE as
defined in (b) below received by VIACELL or any of its AFFILIATES or
SUBLICENSEES ("SELLERS") for the sale or distribution of any PRODUCT to a final
customer who will be the end user of the PRODUCT and is not an AFFILIATE or
SUBLICENSEE ("CUSTOMER"), less (to the extent appropriately documented) the
following amounts actually paid out by VIACELL, its AFFILIATE or SUBLICENSEE or
credited against the amounts received by them from the sale or distribution of
PRODUCT:

              (a) (i) credits and allowances for price adjustment, rejection,
or return of PRODUCTS previously sold;

                  (ii) rebates and cash discounts to purchasers allowed and
taken;

                  (iii) amounts for transportation, insurance, handling or
shipping charges to purchasers;

                  (iv) taxes, duties and other governmental charges levied on or
measured by the sale of PRODUCTS, whether absorbed by VIACELL or paid by the
purchaser so long as VIACELL's price is reduced thereby, but not franchise or
income taxes of any kind whatsoever;

                  (v) charge back payments and/or rebates for PRODUCTS provided
to managed health care organizations, international organizations, or federal,
state, local or other governments, including for example in the United States,
Medicare and Medicaid; and

                  (vi) for any sale in which the United States government on the
basis of its royalty-free license pursuant to 35 USC Sec. 202(c) to any PATENT
RIGHT requires that the GROSS SALES PRICE of any PRODUCT subject to such PATENT
RIGHT be reduced by the amount of such royalty owed GENERAL pursuant to
Paragraph 3.1, the amount of such royalty.

              (b) For any bona fide sale to a bona fide CUSTOMER by VIACELL or
any of its AFFILIATES or SUBLICENSEES, the GROSS SALES PRICE shall be the gross
billing price of the PRODUCT.

                                       2
* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
              (c) If VIACELL or any of its AFFILIATES or SUBLICENSEES sell any
PRODUCT in a bona fide sale as a component of a combination of active functional
elements, the GROSS SALES PRICE of the PRODUCT shall be determined by
multiplying the GROSS SALES PRICE of the combination of the fraction A over A +
B, in which "A" is the GROSS SALES PRICE of the PRODUCT portion of the
combination when sold separately during the ACCOUNTING PERIOD in the country in
which the sale was made, and "B" is the GROSS SALES PRICE of the other active
elements of the combination sold separately during said ACCOUNTING PERIOD in
said country. In the event that no separate sale of either such PRODUCT or
active elements of the combination is made during said ACCOUNTING PERIOD in said
country, the GROSS SALES PRICE of the PRODUCT shall be determined by multiplying
the GROSS SALES PRICE of such combination by the fraction C over C + D, in which
"C" is the standard fully-absorbed cost of the PRODUCT portion of such
combination, and "D" is the sum of the standard fully-absorbed costs of the
other active elements component(s), such costs being arrived at using the
standard accounting procedures of VIACELL which will be in accord with generally
accepted accounting practices.

              (d) If a SELLER commercially uses or disposes of any PRODUCT by
itself (as opposed to use or disposition of the PRODUCT as a component of a
combination of active functional elements) other than in a bona fide sale to a
bona fide CUSTOMER, the GROSS SALES PRICE hereunder shall be the price which
would be then payable in an arm's length transaction with such a CUSTOMER; and
if a SELLER commercially uses or disposes of any PRODUCT as a component of a
combination of active functional elements other than in a bona fide sale to a
bona fide customer, the GROSS SALES PRICE of the PRODUCT shall be determined in
accordance with Paragraph 1.5(c) above, using as the GROSS SALES PRICE of the
combination that price which would be then payable in an arm's length
transaction; provided, however, that SELLERS may use or dispose of PRODUCTS for
clinical trials, and the GROSS SALES PRICE with respect to such PRODUCTS shall
be calculated based on the price, if any, actually billed therefor.

              (e) Transfer of a PRODUCT within VIACELL or between VIACELL and an
AFFILIATE for sale by the transferee shall not be considered a sale, commercial
use or disposition for the purpose of the foregoing paragraphs; in the case of
such transfer the GROSS SALES PRICE shall be based on sale of the PRODUCT by the
transferee.

         1.6 The term "PATENT RIGHT" shall mean the U.S. and foreign patent
applications listed on APPENDIX A, or the equivalent of such applications,
including, without limitation, any division, continuation or any foreign patent
application or Letters Patent or the equivalent thereof issuing thereon or
reissue, reexamination or extension thereof. PATENT RIGHTS shall also include
those claims in any continuation-in-part of the aforementioned patent
applications directed to subject matter specifically described or claimed in
said patent applications.

         1.7 The term "PRODUCT" shall mean any article, device, composition,
method or service the manufacture, use, or sale of which

                                       3

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
              (a) absent the licenses granted herein, would infringe a VALID
CLAIM of any PATENT RIGHT, or

              (b) does not infringe a VALID CLAIM of any PATENT RIGHT licensed
to VIACELL hereunder, but the discovery, development, manufacture or use of
which requires or materially employs non-public KNOW-HOW.

         1.8 The term "SUBLICENSEE" shall mean any non-AFFILIATE third party
granted a license by VIACELL or by an AFFILIATE pursuant to Paragraph 2.1(d). As
used in this Agreement, "SUBLICENSEE" shall include, without limitation, any
third party to whom VIACELL or an AFFILIATE has granted, directly or indirectly,
the right to distribute a PRODUCT, provided that such third party has the
responsibility in whole or in part for marketing and/or promotion of the PRODUCT
within the territory for which such distribution rights are granted.

         1.9 The term "SUBLICENSEE REVENUE" shall mean any payments that VIACELL
receives from a SUBLICENSEE in consideration of the sublicense of the rights
granted to VIACELL under Article 2 including, without limitation, license fees,
milestone payments and license maintenance fees, but excluding the following
payments: (a) royalties on NET SALES by the SUBLICENSEE for which GENERAL
receives its royalties pursuant to Paragraph 5.1, (b) payments made in
consideration of the issuance of equity or debt securities of VIACELL at fair
market value, and (c) payments specifically committed to the research or
development of PRODUCTS actually conducted by or for VIACELL, whether in the
form of funding for future costs or reimbursement for costs previously incurred.

         1.10 The term "KNOW-HOW" shall mean any unpatented technical
information, research data, designs, formulas, process information, clinical
data and other information which is known to Dr. Joel Habener on the EFFECTIVE
DATE and which GENERAL has the right to license, necessary for the exercise or
use of the PATENT RIGHTS in the LICENSE FIELD.

         1.11 The term "VALID CLAIM" shall mean any unexpired issued claim or
pending claim prosecuted in good faith of any PATENT RIGHT that has not been (i)
finally rejected, (ii) declared invalid or unenforceable by a patent office or
court of competent jurisdiction in any unappealed and unappealable decision or
(iii) admitted to be invalid or unenforceable through reissue or disclaimer or
otherwise by the holder thereof.

                                   2. LICENSE

         2.1 GENERAL hereby grants VIACELL, to the extent not prohibited by the
United States Government:

              (a) an exclusive, worldwide, royalty-bearing license in the
LICENSE FIELD under GENERAL's rights in PATENT RIGHTS to make, have made, use,
sell, offer for sale and import PRODUCTS;

                                       4

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
              (b) to the extent an exclusive license is not available to VIACELL
in a country, due to legal or regulatory action in such country, a
non-exclusive, royalty-bearing license in such country in the LICENSE FIELD
under PATENT RIGHTS to make, have made, use, sell, offer for sale and import
PRODUCTS;

              (c) a non-exclusive, worldwide fully paid-up license to use the
KNOW-HOW in the LICENSE FIELD;

              (d) the right to sublicense PATENT RIGHTS and KNOW-HOW licensed to
VIACELL.

         The above licenses to sell PRODUCTS include, without limitation, the
right to grant to the purchaser or recipient of products from VIACELL, its
AFFILIATES, and SUBLICENSEES the right to use such purchased PRODUCTS in a
method coming within the scope of PATENT RIGHTS.

         2.2 (a) It is understood that the granting of any license hereunder is
subject to GENERAL's and GENERAL's AFFILIATES' right to make and to use the
subject matter described and claimed in all PATENT RIGHTS for research, clinical
and educational purposes but for no other purpose, and that if federal funding
supported any PATENT RIGHT, VIACELL's license will be subject to the rights,
conditions and limitations imposed by U.S. law including without limitation the
royalty-free non-exclusive license granted to the U.S. government (see 35 U.S.C.
Section 202 et seq. and regulations pertaining thereto).

              (b) It is further understood that all rights granted in this
Agreement are expressly granted subject to HHMI's institution-wide, paid-up,
non-exclusive, irrevocable license to use the subject matter described and
claimed in all PATENT RIGHTS for its research and other non-commercial purposes
but for no other purpose, without the right to sublicense or assign.

         2.3 Upon request by VIACELL, GENERAL, acting through Dr. Joel Habener,
shall disclose to VIACELL KNOW-HOW. A summary of non-public KNOW-HOW to be
transferred hereunder is attached as APPENDIX D, which may be modified from time
to time by mutual written agreement of the parties (e.g. in the event that such
KNOW-HOW becomes public).

         2.4 GENERAL shall promptly inform VIACELL of any new patent
applications that name Dr. Joel Habener as inventor and that claim the use of
stem cells for treatment of diabetes, provided that such applications are not
encumbered by an agreement with a third party. However, it is understood that
nothing in this Agreement shall be construed to grant VIACELL a license express
or implied under any patent owned solely or jointly by GENERAL other than the
PATENT RIGHTS expressly licensed hereunder.

                          3. DUE DILIGENCE OBLIGATIONS

                                       5

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
         3.1 VIACELL shall itself, or through its AFFILIATES or SUBLICENSEES,
use its reasonable best efforts, based on reasonable business judgment, to
develop and make commercially available PRODUCTS for commercial sales and
distribution throughout the world in the LICENSE FIELD. Such efforts shall
include the following:

         VIACELL shall perform the pre-clinical research and development work
defined in APPENDIX B ("INITIAL OBJECTIVE") within the first 18 months following
the EFFECTIVE DATE. VIACELL, through its parent company, ViaCell, Inc., will
provide funding of $2 million to complete the INITIAL OBJECTIVES. The parties
agree that this sum may need to be revised as a function of the agreed-upon
objectives and shall only include those costs directly incurred in the research
and development of a PRODUCT. VIACELL shall have its own laboratory space,
scientific personnel, and medical/scientific advisory board, which shall be
established and maintained (or, in the case of personnel, hired and employed) at
VIACELL's discretion as needed to achieve the INITIAL OBJECTIVES and any other
development objectives. As a subsidiary of ViaCell, Inc., VIACELL shall have
access to additional personnel and resources of ViaCell, Inc. as needed to
achieve the INITIAL OBJECTIVES and any other development objectives.

         Within sixty (60) days following completion of the INITIAL OBJECTIVES,
VIACELL shall meet the GENERAL and the inventors, to the extent they wish to
participate, to present and discuss the following: (i) results of the initial
research and development work; (ii) proposed business plan for VIACELL; and
(iii) proposed clinical development plan and a commercially reasonable
development timeline. GENERAL and VIACELL shall adopt further time-limited
performance objectives at that time, which objectives shall be appended to this
Agreement as APPENDIX C. Such objectives may include taking the following steps
within defined timeframes: to complete all animal toxicity tests required in
connection with securing U.S. Food and Drug Administration ("FDA") approval of
clinical evaluations thereof; to initiate and thereafter diligently pursue
clinical evaluations of a PRODUCT and in connection therewith take all actions
reasonably necessary under the Food, Drug and Cosmetic Act (21 USC 301-391); to
introduce PRODUCT into all commercially feasible markets.

         Provided, however, that GENERAL shall not unreasonably withhold its
consent to any revision in any time periods specified herein or established in
accordance with this Paragraph 3.1 whenever requested in writing by VIACELL and
supported by evidence of technical difficulties or delays that VIACELL could not
have reasonably avoided. Failure to achieve any objective within the above
stated time periods, or within the time periods established in accordance with
this Paragraph 3.1 or within any extension granted by GENERAL shall result in
GENERAL having the right to cancel upon thirty (30) days notice any exclusive
license granted hereunder or convert any exclusive license to a non-exclusive
license.

         3.2 In the event there is a disagreement between the parties regarding
the proposed business or clinical plans, the parties will engage an objective
third party to advise on the matter and recommend an optimal plan.

                                       6
* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
         3.3 VIACELL shall invite Dr. Joel Habener and Dr. Denise Faustman to
participate as members of the medical/scientific advisory board of VIACELL under
separate consulting agreements.

         3.4 At intervals no longer than every six (6) months, VIACELL shall
report in writing to GENERAL on progress made toward the development and
commercialization of PRODUCTS.

4. FILING, PROSECUTION AND MAINTENANCE OF PATENT RIGHTS AND JOINT PATENT RIGHTS

         4.1 (a) GENERAL shall be responsible for the preparation, filing,
prosecution and maintenance of all patent applications and patents included in
PATENT RIGHTS, at VIACELL's expense. GENERAL shall control patent prosecution of
all PATENT RIGHTS using outside patent counsel acceptable to VIACELL in such
countries as VIACELL shall reasonably specify.

              (b) VIACELL shall reimburse GENERAL for all reasonable costs for
the preparation, filing, prosecution and maintenance of all PATENT RIGHTS
("COSTS") incurred by GENERAL prior to the EFFECTIVE DATE ("PAST PATENT COSTS").
Reimbursement to GENERAL shall be made as follows: Within sixty (60) days
following the execution of this Agreement, GENERAL shall submit to VIACELL an
invoice of the PAST PATENT COSTS, supported by appropriate documentation.
VIACELL shall pay GENERAL fifty percent (50%) of the PAST PATENT COSTS reported
on such invoice within 30 days of receiving said invoice and shall pay the
balance of the PAST PATENT COSTS reported on said invoice on the first
anniversary of the EFFECTIVE DATE. PAST PATENT COSTS are estimated at forty-one
thousand four hundred seventy six dollars and ninety-two cents ($41,476.92),
however, the total COSTS incurred by GENERAL and supported by appropriate
documentation shall be considered the amount of PAST PATENT COSTS to be
reimbursed by VIACELL in accordance with this Paragraph 4.1(b).

              (c) Subject to Paragraph 4.2, VIACELL shall reimburse GENERAL for
all COSTS incurred by GENERAL after the EFFECTIVE DATE and during the term of
this Agreement, within thirty (30) days of receipt of invoices from GENERAL or
its outside counsel as contemplated herein.

         4.2 With respect to any PATENT RIGHT, each document or a draft thereof
pertaining to the filing, prosecution, or maintenance of such PATENT RIGHT,
including but not limited to each patent application, office action, response to
office action, request for terminal disclaimer, and request for reissue or
reexamination of any patent issuing form such application shall be provided to
VIACELL as follows. Documents received from any patent office or counsel's
analysis thereof shall be provided promptly after receipt. For a document to be
filed in any patent office, a draft of such document shall be provided
sufficiently prior to its filing, to the extent practicable at least fourteen
days, to allow for review and comment by VIACELL.

                                       7

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
VIACELL shall have the right to participate in, comment upon and make
recommendations regarding the course of patent prosecution, which
recommendations GENERAL agrees to follow except to the extent such
recommendations result, in GENERAL's determination, in an unwarranted narrowing
of PATENT RIGHTS. In no event shall GENERAL allow the PATENT RIGHTS to be
narrowed without providing advance written notice to VIACELL.

         4.3 If VIACELL shall elect not to pay or continue to pay the COSTS for
any PATENT RIGHT, VIACELL shall so notify GENERAL promptly and VIACELL shall
thereafter be relieved of the obligation to pay any additional COSTS regarding
such PATENT RIGHT incurred after the receipt of such notice by GENERAL. Such
U.S. or foreign patent application or patent shall thereupon cease to be a
PATENT RIGHT hereunder and GENERAL shall be free to prosecute or maintain such
PATENT RIGHT at its own expense and to license its rights to that particular
PATENT RIGHT to any other party on any terms.

                                  5. PAYMENTS

         5.1 Beginning with the FIRST COMMERCIAL SALE in any country, on all
sales of PRODUCTS anywhere in the world by VIACELL, its AFFILIATES or
SUBLICENSEES, VIACELL shall pay GENERAL royalties in accordance with the
following schedule, such undertaking and schedule having been agreed to for the
purpose of reflecting and advancing the mutual convenience of the parties. For
each PRODUCT sold by VIACELL or its AFFILIATES and SUBLICENSEES:

              (a) [*] of the NET SALES PRICE so long as the PRODUCT, its
manufacture, use or sale is covered by a VALID CLAIM of any PATENT RIGHT in the
country of sale licensed exclusively to VIACELL; and

              (b) [*] of the NET SALES PRICE whenever the PRODUCT, its
manufacture, use or sale is covered by VALID CLAIM of any PATENT RIGHT in the
country of sale licensed non-exclusively to VIACELL; and

              (c) During each of the ten (10) years next following the FIRST
COMMERCIAL SALE anywhere in the world by VIACELL, its AFFILIATES or
SUBLICENSEES, [*] of the NET SALES PRICE on which no royalty is payable under
Paragraph 5.1(a) or 5.1(b) above.

         5.2 (a) In the event that more than one royalty rate under Paragraph
5.1 is applicable to a PRODUCT, the highest of the applicable royalties shall
apply.

              (b) Only one royalty under Paragraph 5.1 shall be due and payable
to GENERAL by VIACELL for any PRODUCT regardless of the number of PATENT RIGHTS
covering such PRODUCT.

              (c) In the event VIACELL is required to license any technology of
a third party in order to make, use, sell, offer for sale or import PRODUCTS,
then the royalty payment

                                       8

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
due to GENERAL under Paragraph 5.1 shall be reduced by fifty percent (50%) of
the royalties paid by VIACELL under such third party license; provided, however,
that in no event shall the royalty payable to GENERAL under Paragraph 5.1 be
reduced by more than fifty percent (50%) in any ACCOUNTING PERIOD.

              (d) If any license granted pursuant to Article 2 shall be or
become non-exclusive and GENERAL shall license any PATENT RIGHT to another
licensee for the purpose of making, using, selling, offering for sale or
importing PRODUCTS and accept a royalty or royalties more favorable to such
licensee than herein provided for, GENERAL shall give written notice thereof to
VIACELL AND as of the effective time of such more favorable royalty or
royalties, VIACELL's obligation hereunder to pay royalty or royalties to GENERAL
shall be revised to the more favorable rate provided the licensee.

              (e) In the event that the royalty paid to GENERAL hereunder is a
significant factor in the return realized by VIACELL so as to diminish VIACELL's
capability to respond to competitive pressures in the market, GENERAL agrees to
consider a reasonable reduction in the royalty paid to GENERAL as to each such
PRODUCT for the period during which such market condition exists. Factors
determining the size of the reduction will include profit margin on PRODUCT and
on analogous products, prices of competitive products, total prior sales by
VIACELL, and VIACELL's expenditures in PRODUCT development.

         5.3 Subject to Paragraph 5.4, VIACELL shall pay GENERAL [*] of all
SUBLICENSEE REVENUE received by VIACELL. Such payments shall be due and payable
within sixty (60) days after VIACELL receives the relevant payment from the
SUBLICENSEE.

         5.4 VIACELL shall pay GENERAL the following amounts upon the occurrence
of the following milestones, which amounts are due no more than once for each
PRODUCT:

              (a) upon filing the first Investigational New Drug (IND)
application for each PRODUCT by VIACELL or an AFFILIATE or SUBLICENSEE: the
greater of (i) [*] or (ii) [*] of any SUBLICENSEE REVENUE received by VIACELL
attributable to this event;

              (b) upon commencement of the first Phase III clinical trial of
each PRODUCT by VIACELL or an AFFILIATE or SUBLICENSEE: the greater of (i) [*]
or (ii) [*] of any SUBLICENSEE REVENUE received by VIACELL attributable to the
commencement of the first Phase III clinical trial of such PRODUCT;

              (c) upon filing with the FDA of the first Biologics License
Application (BLA), or comparable application with respect to each PRODUCT by
VIACELL or an AFFILIATE or SUBLICENSEE: the greater of (i) [*] or (ii) [*] of
any SUBLICENSEE REVENUE received by VIACELL attributable to the filing with the
FDA of the first BLA or comparable application with respect to such PRODUCT; and

                                       9

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
              (d) upon approval by the FDA of the first BLA or comparable
application with respect to each PRODUCT by VIACELL or an AFFILIATE or
SUBLICENSEE: the greater of (i) [*] or (ii) [*] of any SUBLICENSEE REVENUE
received by VIACELL attributable to the approval by the FDA of the first BLA or
comparable application with respect to such PRODUCT.

         5.5 VIACELL shall pay GENERAL an annual minimum payment of thirty
thousand dollars ($30,000) per calendar year, commencing with the calendar year
beginning thirty (30) months from the EFFECTIVE DATE, i.e. on September 15,
2004. The annual minimum payment for each year shall be due within thirty (30)
days of said month and day, and VIACELL may credit all payments made to GENERAL
under this Article 5 during the prior twelve (12) month period against such
annual minimum payment due each year.

         5.6 The payments due under this Agreement shall, if overdue, bear
interest until payment at a per annum rate equal to one percent (1%) above the
prime rate in effect at the Fleet Bank on the due date, not to exceed the
maximum permitted by law. The payment of such interest shall not preclude
GENERAL from exercising any other rights it may have as a consequence of the
lateness of any payment.

                            6. REPORTS AND PAYMENTS

         6.1 VIACELL shall keep, and shall cause each of its AFFILIATES and
SUBLICENSEES, if any, to keep full and accurate books of accounts containing all
particulars that may be necessary for the purpose of calculating all royalties
payable to GENERAL. Such books of account shall be kept at their principal place
of business and, with all necessary supporting data shall, during all reasonable
times, for the three (3) years next following the end of the calendar year to
which each shall pertain, be open for inspection at reasonable times after
reasonable written notice by GENERAL or its designee at GENERAL's expense for
the purpose of verifying royalty statements or compliance with this Agreement.
If the results of such audit demonstrate under-reporting of greater than five
percent (5%) VIACELL shall pay the costs of the audit.

         6.2 In each year the amount of royalty due shall be calculated
semiannually as of the end of each ACCOUNTING PERIOD and shall be paid
semiannually within the sixty (60) days next following such date, every such
payment to be supported by the accounting prescribed in Paragraph 6.3 and to be
made in United States currency. Whenever conversion from any foreign currency
shall be required, such conversion shall be at the rate of exchange thereafter
published in the Wall Street Journal for the business day closest to the end of
the applicable ACCOUNTING PERIOD.

         6.3 With each semiannual payment, VIACELL shall deliver to GENERAL a
full and accurate accounting to include at least the following information:

                                       10

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
              (a) Quantity of each PRODUCT sold or leased (by country) by
VIACELL, and its AFFILIATES or SUBLICENSEES;

              (b) Total billings for each PRODUCT (by country);

              (c) Quantities of each PRODUCT used by VIACELL and its AFFILIATES
or SUBLICENSEES;

              (d) Names and addresses of all SUBLICENSEES of VIACELL; and

              (e) Total royalties payable to GENERAL.

                                7. INFRINGEMENT

         7.1 GENERAL will protect its PATENT RIGHTS from infringement and
prosecute infringers when, in its sole judgement, such action may be reasonably
necessary, proper and justified.

         7.2 If VIACELL shall have supplied GENERAL with written evidence
demonstrating to GENERAL's reasonable satisfaction prima facie infringement of a
claim of a PATENT RIGHT in the LICENSE FIELD by a third party, VIACELL may by
notice request GENERAL to take steps to protect the PATENT RIGHT. GENERAL shall
notify VIACELL within three (3) months of the receipt of such notice whether
GENERAL intends to prosecute the alleged infringement. If GENERAL notifies
VIACELL that it intends to prosecute, GENERAL shall, within three (3) months of
its notice to VIACELL either (i) cause infringement to terminate or (ii)
initiate legal proceedings against the infringer. In the event GENERAL notifies
VIACELL that GENERAL does not intend to prosecute said infringement VIACELL may,
upon notice to GENERAL, initiate legal proceedings against the infringer at
VIACELL's expense and in GENERAL's name if so required by law. No settlement,
consent judgment or other voluntary final disposition of the suit which
invalidates or restricts the claims of such PATENT RIGHTS may be entered into
without the consent of GENERAL, which consent shall not be reasonably withheld.
VIACELL shall indemnify GENERAL against any order for payment that may be made
against GENERAL in such proceedings.

         7.3 In the event one party shall initiate or carry on legal proceedings
to enforce any PATENT RIGHT against any alleged infringer or defend a
declaratory judgment action as provided in Paragraph 7.5, the other party shall
fully cooperate with and supply all assistance reasonably requested by the party
initiating or carrying on such proceedings. The party which institutes any suit
to protect or enforce a PATENT RIGHT shall have sole control of that suit and
shall bear the reasonable expenses (excluding legal fees) incurred by said other
party in providing such assistance and cooperation as is requested pursuant to
this Paragraph 7.3. The party initiating or carrying on such legal proceedings
shall keep the other party informed of the progress of such proceeding and aid
other party shall be entitled to counsel in such proceedings but at its own
expense. Any award paid by third parties as the result of such proceeding

                                       11

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
(whether by way of settlement or otherwise) shall first be applied to
reimbursement of the unreimbursed legal fees and expenses incurred by either
party and the payment to GENERAL of royalties withheld pursuant to Paragraph
7.6, and then the remainder shall be divided between the parties as follows:

              (a) (i) If the amount is based on lost profits, VIACELL shall
receive an amount equal to the damages the court determines VIACELL has suffered
as a result of the infringement less the amount of any royalties that would have
been due GENERAL on sales of PRODUCT lost by VIACELL as a result of the
infringement had VIACELL made such sales; and

                  (ii) GENERAL shall receive an amount equal to the royalties it
would have received if such sales had been made by VIACELL; and

               (b) As to awards other than those based on lost profits, sixty
percent (60%) to the party initiating such proceedings and forty percent (40%)
to the other party.

         7.4 For the purpose of the proceedings referred to in this Article 7,
the GENERAL and VIACELL shall permit the use of their names and shall execute
such documents and carry out such other acts as may be necessary. The party
initiating or carrying on such legal proceedings shall keep the other party
informed of the progress of such proceedings and said other party shall be
entitled to counsel in such proceedings but at its own expense, said expenses to
be offset against any damages received by the party bringing suit in accordance
with the foregoing Paragraph 7.3.

         7.5 In the event that the declaratory judgment action or any other
action alleging invalidity, unenforceability, or non-infringement of any of the
PATENT RIGHTS shall be brought, VIACELL or GENERAL shall promptly notify the
other party. VIACELL shall have the sole right to defend such action at its own
expense, unless GENERAL, within thirty (30) days after notification of such
action, elects to intervene and take over the sole defense of the action at its
own expense.

         7.6 VIACELL may offset a total of fifty percent (50%) of expenses
incurred by it pursuant to this Article 7 against any amounts payable to GENERAL
under Article 5, provided, however, that in no event shall amount due GENERAL
under Article 5 be reduced by more than fifty percent (50%) in any ACCOUNTING
PERIOD, and provided, further, any reduction hereunder, or portion thereof, that
is rendered not usable pursuant to the immediately preceding proviso may be
carried forward for use in a future ACCOUNTING PERIOD. For clarity, in the event
that VIACELL offsets its expenses pursuant to this Article 7 as well as royalty
payments due to third parties under Paragraph 5.1(c), the combined offsets shall
not reduce amounts due GENERAL under Article 5 by more than fifty percent (50%)
in any ACCOUNTING PERIOD.

                               8. INDEMNIFICATION

                                       12

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
         8.1 (a) VIACELL shall indemnify, defend and hold harmless GENERAL and
its trustees, officers, medical and professional staff, employees, and agents
and their respective successors, heirs and assigns (the "MGH INDEMNITEES"),
against any liability, damage, loss or expense (including reasonable attorney's
fees and expenses of litigation) incurred by or imposed upon the MGH INDEMNITEES
or any one of them in connection with any claims, suits, actions, demands or
judgments arising out of any theory of product liability (including, but not
limited to, actions in the form of tort, warranty, or strict liability)
concerning any product, process or service, made, used or sold pursuant to any
right or license granted under this Agreement.

               (b) VIACELL's indemnification under (a) above shall not apply to
any liability, damage, loss or expense that it is directly attributable to the
negligent activities, reckless misconduct or intentional misconduct of the MGH
INDEMNITEES.

               (c) VIACELL agrees, at its own expense to provide attorneys
reasonable acceptable to GENERAL to defend against any actions brought or filed
against any MGH INDEMNITEES with respect to the subject of indemnity contained
herein, whether or not such actions are rightfully brought.

               (d) This paragraph 8.1 shall survive expiration or termination of
this Agreement.

         8.2 (a) HHMI and its trustees, officers, employees, and agents
(collectively, "HHMI INDEMNITEES", and together with the MGH INDEMNITEES, the
"INDEMNITEES") will be indemnified, defended by counsel reasonably acceptable to
HHMI and held harmless by VIACELL from and against any claim, liability, cost,
expense, damage, deficiency, loss, or obligation, of any kind or nature
(including, without limitation, reasonable attorneys' fees and other costs and
expenses of defense) (collectively, "CLAIMS"), based upon, arising out of, or
otherwise relating to this Agreement, including, without limitation, any cause
of action relating to product liability. The previous sentence will not apply to
any Claim that is determined with finality by a court of competent jurisdiction
to result solely from the gross negligence or willful misconduct of an HHMI
INDEMNITEE.

               (b) This Paragraph 8.2 shall survive expiration or termination of
this Agreement.

         8.3 (a) For the indemnification obligations of VIACELL contained in
Paragraphs 8.1 and 8.2 above, the following procedures shall apply: all
INDEMNITEES hereunder agree to provide VIACELL with prompt written notice of any
claim, suit, action, demand, or judgment for which indemnification is sought
under this Agreement. In the case of an HHMI INDEMNITEE, notice shall be given
reasonably promptly following actual receipt of written notice thereof by an
officer or attorney of HHMI. Notwithstanding the foregoing, the delay or failure
of an HHMI INDEMNITEE to give reasonably prompt notice to VIACELL of any such
claim shall not affect the rights of such HHMI INDEMNITEE unless, and then only
to the extent

                                       13

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
that, such delay or failure is prejudicial to or otherwise adversely affects
VIACELL. VIACELL agrees, at its own expense, to provide attorneys reasonably
acceptable to the applicable INDEMNITEES to defend against any such claim. The
applicable INDEMNITEES shall cooperate fully with VIACELL in such defense and
will permit VIACELL to conduct and control such defense and the disposition of
such claims, suit, or action (including, without limitation, all decisions
relative to litigation, appeal, and settlement; provided, however, that any
INDEMNITEE shall have the right to retain its own counsel, at the expense of
VIACELL, if representation of such INDEMNITEE by the counsel retained by VIACELL
would be inappropriate because of actual or potential differences in the
interests of such INDEMNITEE and any other party represented by such counsel.
VIACELL agrees not to settle any CLAIM against an HHMI INDEMNITEE without HHMI's
written consent, where (a) such settlement would include any admission of
liability on the part of any HHMI INDEMNITEE, (b) such settlement would impose
any restriction on any HHMI INDEMNITEE's conduct of any of its activities, or
(c) such settlement would not include an unconditional release of all HHMI
INDEMNITEES from all liability for claims that are the subject matter of the
settled CLAIM. VIACELL agrees to keep GENERAL and HHMI, as the case may be,
informed of the progress in the defense and disposition of any such claim.

               (b) This Paragraph 8.3 shall survive expiration or termination of
this Agreement.

         8.4 (a) Beginning at such time as any LICENSED PRODUCT is being
commercially distributed or sold for use in the LICENSED FIELD (other than for
the purpose of obtaining regulatory approvals) by VIACELL or by a SUBLICENSEE,
AFFILIATE or agent of VIACELL, VIACELL shall, at its sole cost and expense,
procure and maintain commercial general liability insurance in amounts not less
than $2,000,000 per incident and $2,000,000 annual aggregate and naming the
INDEMNITEES as additional insureds. Such commercial general liability insurance
shall prove (i) product liability coverage and (ii) broad form contractual
liability coverage for VIACELL's indemnification under Paragraphs 8.1 and 8.2 of
this Agreement. If VIACELL elects to self-insure all or part of the limits
described above (including deductibles or retentions which are in excess of
$250,000 annual aggregate) such self-insurance program must be reasonably
acceptable to GENERAL and the Risk Management Foundation. The minimum amounts of
insurance coverage required under this Paragraph 8.3 shall not be construed to
create a limit of VIACELL's liability with respect to its indemnification under
Paragraphs 8.1 and 8.2 of this Agreement.

               (b) VIACELL shall provide GENERAL with written evidence of such
insurance upon request of GENERAL. VIACELL shall provide GENERAL with written
notice at least fifteen (15) days prior to the cancellation, non-renewal or
material change in such insurance; if VIACELL does not obtain replacement
insurance providing comparable coverage prior to the expiration of such fifteen
(15) day period, GENERAL shall have the right to terminate this Agreement
effective at the end of such fifteen (15) day period without notice or any
additional waiting periods.

                                       14

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
               (c) VIACELL shall maintain such commercial general liability
insurance beyond the expiration or termination of this Agreement during (i) the
period that any LICENSED PRODUCT is being commercially distributed or sold for
use in the LICENSED FIELD (other than for the purpose of obtaining regulatory
approvals) by VIACELL or by a SUBLICENSEE, AFFILIATE or agent of VIACELL and
(ii) a reasonable period after the period referred to in (c)(i) above which in
no event shall be less than fifteen (15) years.

               (d) This Paragraph 8.4 shall survive expiration or termination of
this Agreement.

         8.5 OTHER THAN REPRESENTATIONS AND WARRANTIES SET FORTH HEREIN
(INCLUDING, WITHOUT LIMITATION, THE PREAMBLES), GENERAL MAKES NO REPRESENTATION
OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED
WARRANTY OF MERCHANTABILITY OR ANY IMPLIED WARRANTY OF FITNESS FOR A PARTICULAR
PURPOSE WITH RESPECT TO ANY PATENT, KNOW-HOW, TRADEMARK SOFTWARE, TRADE SECRET,
TANGIBLE RESEARCH PROPERTY, INFORMATION OR DATA LICENSED OR OTHERWISE PROVIDED
TO VIACELL HEREUNDER AND HEREBY DISCLAIMS THE SAME.

         8.6 UNDER NO CIRCUMSTANCES SHALL EITHER PARTY BE ENTITLED TO RECOVER
FROM THE OTHER ANY INCIDENTAL, CONSEQUENTIAL, INDIRECT, SPECIAL, EXEMPLARY OR
PUNITIVE DAMAGES; provided, however, that this Paragraph 8.6 shall in no way
reduce or limit VIACELL's obligations under the foregoing Paragraphs 8.1 and
8.2. This Paragraph 8.6 shall survive expiration or termination of this
Agreement.

         8.7 GENERAL represents that, to the best of its knowledge as of the
EFFECTIVE DATE, there are no contractual obligations to other sponsors of
research at GENERAL that would prohibit the granting of the rights and licenses
granted to VIACELL herein.

         8.8 HHMI is not a party to this Agreement and has no liability to any
licensee, sublicensee, or user of anything covered by this Agreement, but HHMI
is an intended third-party beneficiary of this Agreement and certain of its
provisions are for the benefit of HHMI and are enforceable by HHMI in its own
name. This Paragraph 8.8 shall survive expiration or termination of this
Agreement.

                                 9. TERMINATION

         9.1 Unless otherwise terminated as provided for in this Agreement, the
license to PATENT RIGHTS granted hereunder will continue on a country by country
basis:

               (a) for one (1) year after the date VIACELL, its AFFILIATES, or
SUBLICENSEES shall last sell any PRODUCT in such country, it being understood
that

                                       15

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
GENERAL shall have the right to notify VIACELL in accordance with the
termination provisions contained in Paragraph 9.3 so as to terminate such
license in any country in the event that after the FIRST COMMERCIAL SALE of
PRODUCT in such country there is a continuous one (1) year period in which no
PRODUCT is sold in such country, provided such sale is not prevented by force
majeure, government regulation or intervention, or institution of a lawsuit by
any third party, or

               (b) until the last to expire of any PATENT RIGHT, the claims of
which but for this Agreement would be infringed by the manufacture, use or sale
of any PRODUCT in the applicable country, whichever shall first occur.

         9.2 VIACELL may terminate this Agreement at any time upon written
notice to GENERAL following completion of the INITIAL OBJECTIVES.

         9.3 If either party shall fail to faithfully perform any of its
obligations under this Agreement except the due-diligence milestones specified
in Article 3 herein, the non-defaulting party may give written notice of the
default to the defaulting party specifying in reasonable detail the default. The
parties shall thereafter consult concerning the alleged default, and unless such
default is corrected within forty-five (45) days after such notice, the
notifying party may terminate this Agreement and the license hereunder upon
forty-five (45) days prior written notice, provided that only one such
forty-five (45) day grace period shall be available in any twelve (12) month
period with respect to a default of any particular provision hereunder.
Thereafter notice of default of said provision shall constitute termination.

         9.4 In the event that any license granted to VIACELL under this
Agreement is terminated, any sublicense under such license granted prior to
termination of said license shall remain in full force and effect, provided
that:

               (a) the SUBLICENSEE is not then in breach of its sublicense
agreement;

               (b) the SUBLICENSEE agrees to be bound to GENERAL as the licensor
under the terms and conditions of its sublicense agreement, as modified by the
provisions of this Paragraph 9.3;

               (c) the SUBLICENSEE, at GENERAL's written request, assumes in a
signed writing the same obligations to GENERAL as those assumed by VIACELL under
Articles 8 and 10 hereof;

               (d) GENERAL shall have the right to receive the greater of (a)
any payments payable to VIACELL under such sublicense agreement to the extent
they are reasonably and equitably attributable to such SUBLICENSEE's right under
such sublicense to use and exploit PATENT RIGHTS and KNOW-HOW or (b) the lowest
royalty which is within the "Competitive" range as hereinafter defined, at the
time GENERAL's license to VIACELL is terminated. A royalty rate shall be
regarded as "Competitive" if it is within the range of royalty

                                       16

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
rates that GENERAL would charge in an arm's length transaction with a licensee
which was not and had not been a sponsor of research at GENERAL, taking into
account the value of the licensed technology at the time GENERAL's license to
VIACELL is terminated;

               (e) the SUBLICENSEE agrees to be bound by the due diligence
obligations of VIACELL pursuant to Paragraph 3.1 hereof (whether set by the
parties or by Alternate Dispute Resolution pursuant to Paragraph 10.10) in the
field and territory of the sublicense;

               (f) GENERAL has the right to terminate such sublicense upon
fifteen (15) days prior written notice to VIACELL and such SUBLICENSEE in the
event of any material breach of the obligation to make the payments described in
clause (d) of this Paragraph 9.4, unless such breach is cured prior to the
expiration of such fifteen (15) day period, and shall further have the right to
terminate such sublicense in the event of SUBLICENSEE's failure to meet its due
diligence obligations pursuant to clause (e) of this Paragraph 9.4;

               (g) GENERAL shall not assume, and shall not be responsible to
such SUBLICENSEE for, any representations, warranties or obligations of VIACELL
to such SUBLICENSEE, other than to permit such SUBLICENSEE to exercise any
rights to PATENT RIGHTS and KNOW-HOW that are granted under such sublicense
agreement consistent with the terms of this Agreement.

         9.5 Upon termination of any license hereunder VIACELL shall pay GENERAL
all royalties due or accrued on (i) the sale of PRODUCT up to and including the
date of termination and (ii) for twelve (12) months following the date of
termination, the sale of PRODUCT manufactured prior to the termination date.

                               10. MISCELLANEOUS

         10.1 This Agreement constitutes the entire understanding between the
parties with respect to the subject matter hereof and supersedes all prior
agreements and understandings between the parties pertaining to the subject
matter hereof.

         10.2 In order to facilitate implementation of this Agreement, GENERAL
and VIACELL are designating the following individuals to act on their behalf
with respect to this Agreement for the matter indicated below:

               (a) with respect to all royalty payments, any correspondence
pertaining to any PATENT RIGHT, or any notice of the use of GENERAL's name, for
GENERAL, the Director, Corporate Sponsored Research and Licensing and for
VIACELL, Director, Business Development, ViaCell, Inc., One Innovation Drive,
Worcester, Massachusetts 01605, with a copy to Senior Vice-President of Business
Development, ViaCell, Inc., 131 Clarendon Street, Boston, Massachusetts 02116;
provided that correspondence relating to the billing of patent costs shall also
be copied to, for GENERAL, the Business Manager, Corporate Sponsored Research
and Licensing.

                                       17

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
               (b) any amendment of or waiver under this Agreement, any written
notice (including, without limitation, progress reports or other communication
pertaining to the Agreement): for GENERAL, the Director, Corporate Sponsored
Research and Licensing; and for VIACELL, Director, Business Development,
ViaCell, Inc., One Innovation Drive, Worcester, Massachusetts 01605, with a copy
to Senior Vice-President of Business Development, ViaCell, Inc., 131 Clarendon
Street, Boston, Massachusetts 02116.

               (c) the above designations may be superseded from time to time by
alternative designations made by: for GENERAL, the Vice President for Corporate
Sponsored Research and Licensing and for VIACELL, Director, Business
Development, ViaCell, Inc., One Innovation Drive, Worcester, Massachusetts
01605.

         Any notices required or permitted under this Agreement shall be in
writing, shall specifically refer to this Agreement, and shall be sent by hand,
recognized national overnight courier, or registered or certified mail, postage
prepaid, return receipt requested, to the appropriate addresses specified above,
and shall be effective upon receipt.

         10.3 This Agreement may be amended and any of its terms or conditions
may be waived only by a written instrument executed by the parties or, in the
case of a waiver, by the party waiving compliance. The failure of either party
at any time or times to require performance of any provision hereof shall in no
manner affect its rights at a later time to enforce the same. No waiver by
either party of any condition shall be deemed as a further or continuing waiver
of such condition or term or of any other condition or term.

         10.4 This Agreement shall be binding upon and inure to the benefit of
and be enforceable by the parties hereto and their respective legal
representatives, successors and permitted assigns.

         10.5 Any delays in or failures of performance by either party under
this Agreement shall not be considered a breach of this Agreement if and to the
extent caused by occurrences beyond the reasonable control of the party
affected, including but not limited to: Acts of God; acts, regulations or laws
of any government; strikes or their concerted acts of worker; fires; floods;
explosions; riots, wars; rebellion; action, inaction or delay by any
governmental authority; bankruptcy of third parties; and sabotage. Any time for
performance hereunder shall be extended by the actual time or delay caused by
such occurrence.

         10.6 Neither party shall use the name of the other party of any staff
member, officer, employee or student of the other party or any adaptation
thereof in any advertising, promotional or sales literature, publicity or in any
document employed to obtain funds or financing without the prior written
approval of the party or individual whose name is to be used. For GENERAL, such
approval shall be obtained from the Director of Public Affairs.

         10.7 This Agreement shall be governed by and construed and interpreted
in accordance with the laws of the Commonwealth of Massachusetts without regard
to conflicts of laws

                                       18

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
principles, except that questions concerning the validity, enforceability,
construction or effect of any PATENT RIGHTS shall be determined by the law of
the country in which such PATENT RIGHT shall have been granted.

         10.8 This Agreement shall not be assignable by GENERAL without
VIACELL's written consent except for the right to receive royalties or other
payments payable herein. VIACELL may at its own discretion and without approval
by GENERAL transfer its interest or any part thereof under this Agreement to its
parent corporation or an AFFILIATE in the event VIACELL is dissolved following
completion of the INITIAL OBJECTIVES, or, in the event of merger, consolidation
or sale of substantially all of VIACELL's assets or that portion of VIACELL's
business to which this Agreement relates, to the purchaser or assignee of said
assets or to the surviving entity in any merger, consolidation or acquisition.
In the event of any such transfer, the transferee shall assume and be bound by
the provisions of this Agreement. Otherwise this Agreement shall be assignable
by VIACELL only with the consent in writing of GENERAL.

         10.9 In the event VIACELL becomes independent from its parent
corporation (i.e., establishes a separate ownership structure from ViaCell,
Inc.), VIACELL and GENERAL may elect to renegotiate the terms of this Agreement
to achieve a structure and terms more suitable to VIACELL as an independent
entity.

         10.10 For any and all claims, disputes, or controversies arising under,
out of, or in connection with this Agreement, except claims, disputes, or
controversies affecting the rights or property of HHMI or the validity,
enforceability, construction, or effect of any PATENT RIGHT, which the parties
shall be unable to resolve within sixty (60) days, the party raising such
dispute shall promptly advise the other party of such claim, dispute, or
controversy in a writing which describes in reasonable detail the nature of such
dispute. By not later than five (5) business days after the recipient has
received such notice of dispute, each party shall have selected for itself a
representative who shall have the authority to bind such party and shall
additionally have advised the other party in writing of the name and title of
such representative. By not later than ten (10) business days after the date of
such notice of dispute, such representatives shall agree upon a third party
which is in the business of providing Alternative Dispute Resolution (ADR)
services (hereinafter, "ADR Provider") and shall schedule a date with such ADR
Provider to engage in ADR. Thereafter, the representatives of the parties shall
engage in good faith in an ADR process under the auspices of the selected ADR
Provider. If within the aforesaid thirty (30) business days after the date of
the notice of dispute the representatives of the parties have not been able to
agree upon an ADR Provider and schedule a date to engage in ADR, or if they have
not been able to resolve the dispute within thirty (30) business days after the
termination of ADR, the parties shall have the right to pursue any other
remedies legally available to resolve such dispute in either the Courts of the
Commonwealth of Massachusetts or in the United States District Court for the
District of Massachusetts, to whose jurisdiction for such purposes each of
GENERAL and VIACELL hereby irrevocably consents and submits (except for any
matters which may not be heard in any such courts because it lacks subject
matter jurisdiction, which matters may be heard in the appropriate judicial
forum).

                                       19

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
Notwithstanding the foregoing, nothing in this Paragraph 10.10 shall be
construed to waive any rights or timely performance of any obligations existing
under this Agreement.

         10.11 If any provision(s) of this Agreement are or become invalid, are
ruled illegal by any court of competent jurisdiction or are deemed unenforceable
under then current applicable law from time to time in effect during the term
hereof, it is the intention of the parties that the remainder of this agreement
shall not be effected thereby. It is further the intention of the parties that
in lieu of each such provision which is invalid, illegal or unenforceable, there
be substituted or added as part of this Agreement a provision which shall be as
similar as possible in economic and business objectives as intended by the
parties to such invalid, illegal or enforceable provision, but shall be valid,
legal and enforceable.

         10.12 The captions herein have been inserted solely for convenience of
reference and in no way define or limit the scope or substance of any provision
of this Agreement. As used in this Agreement, "herein" and "hereof" shall refer
to this Agreement as a whole. Facsimile execution and delivery of this Agreement
by either party shall be legal, valid and binding.

                                     ******

                                       20

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.

<PAGE>
         THE PARTIES have duly executed this Agreement as of the date first
shown above written.

VIACELL, INC.                           THE GENERAL HOSPITAL CORPORATION

BY: Signature on File                   BY: Signature on File
    ------------------------------          -------------------------------

TITLE: Senior Vice President            TITLE: Director
       ---------------------------             ----------------------------

DATE: 3/15/02                           DATE: 3/15/02
      ----------------------------                   ----------------------

                                       21

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
                                   APPENDIX A

                                  PATENT RIGHTS

                                     MGH [*]

                                       22

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
                                   APPENDIX B

                               INITIAL OBJECTIVES

                                       [*]

                                       23

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
                                   APPENDIX C

                             PERFORMANCE OBJECTIVES

              (TO BE DEVISED UPON COMPLETION OF INITIAL OBJECTIVES)

                                       24

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
                                   APPENDIX D

                               NON-PUBLIC KNOW-HOW

                      (TO BE COMPLETED BY DR. JOEL HABENER)

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.

                                       25<PAGE>
                                                                   Exhibit 10.21

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS
([**]), HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED

                      MASSACHUSETTS INSTITUTE OF TECHNOLOGY

                                       AND

                           VIACELL NEUROSCIENCE, INC.

                       EXCLUSIVE PATENT LICENSE AGREEMENT

              Offer to this agreement is open until August 20, 2002

<PAGE>
                                TABLE OF CONTENTS

<TABLE>
<S>                                                                          <C>
TABLE OF CONTENTS.....................................................        ii
RECITALS..............................................................         1
1.  Definitions.......................................................         2
2.  Grant of Rights...................................................         6
3.  COMPANY Diligence Obligations.....................................         8
4.  Royalties and Payment Terms.......................................        10
5.  Reports and Records...............................................        12
6.  Patent Prosecution................................................        15
7.  Infringement......................................................        16
8.  Indemnification and Insurance.....................................        17
9.  No Representations or Warranties..................................        19
10. Assignment........................................................        19
11. General Compliance with Laws......................................        19
12. Termination.......................................................        20
13. Dispute Resolution................................................        21
14. Miscellaneous.....................................................        22
APPENDIX A............................................................        25
APPENDIX B............................................................        26
</TABLE>

                                       ii
<PAGE>
                      MASSACHUSETTS INSTITUTE OF TECHNOLOGY
                       EXCLUSIVE PATENT LICENSE AGREEMENT

      This Agreement, effective as of the date set forth above the signatures of
the parties below (the "EFFECTIVE DATE"), is between the Massachusetts Institute
of Technology ("M.I.T."), a Massachusetts corporation, with a principal office
at 77 Massachusetts Avenue, Cambridge, MA 02139-4307 and ViaCell Neuroscience,
Inc ("COMPANY"), a Delaware corporation and a wholly-owned subsidiary of
ViaCell, Inc. with a principal place of business at 131 Clarendon Street,
Boston, MA 02116.

                              R E C I T A L S

      WHEREAS, M.I.T. is the owner of certain PATENT RIGHTS (as later defined
herein) relating to M.I.T. Case No. 9265, "A Novel Fibroblast Growth Factor
Dimer", by Chi-pong Kwan, Rahul Raman, Ram Sasisekharan, Zachary Shriver, and
Ganesh Venkataraman and has the right to grant licenses under said PATENT
RIGHTS, subject only to a royalty-free, nonexclusive non-transferable license to
practice the PATENT RIGHTS granted to the United States Government for
government purposes;

      WHEREAS, M.I.T. desires to have the PATENT RIGHTS developed and
commercialized to benefit the public and is willing to grant a license
thereunder;

      WHEREAS, COMPANY has represented to M.I.T., to induce M.I.T. to enter into
this Agreement, that COMPANY shall commit itself to a thorough, vigorous and
diligent program of exploiting the PATENT RIGHTS with the intent that public
utilization shall result therefrom; and

      WHEREAS, COMPANY desires to obtain a license under the PATENT RIGHTS upon
the terms and conditions hereinafter set forth.

      NOW, THEREFORE, M.I.T. and COMPANY hereby agree as follows:
<PAGE>
                              1. DEFINITIONS.

      1.1 "AFFILIATE" shall mean any legal entity (such as a corporation,
partnership, or limited liability company) that is controlled by COMPANY. For
the purposes of this definition, the term "control" means (i) beneficial
ownership of at least fifty percent (50%) of the voting securities of a
corporation or other business organization with voting securities or (ii) a
fifty percent (50%) or greater interest in the net assets or profits of a
partnership or other business organization without voting securities.

      1.2 "BIOLOGICS LICENSE APPLICATION" or "BLA" shall mean a Biologics
License Application or similar application, such as a New Drug Application or
Marketing Approval Authorization, filed with the FDA after completion of human
clinical trials to obtain marketing approval of a LICENSED PRODUCT or a LICENSED
SERVICE.

      1.3 "CORPORATE PARTNER" shall mean: a) any non-AFFILIATE entity which
agrees to compensate (either in cash or non-cash) COMPANY for any one or more of
the rights to market, distribute, sell, use, and/or transfer LICENSED PRODUCTS
and/or LICENSED PROCESSES, or b) any non-AFFILIATE entity which agrees to
compensate (either in cash or non-cash) COMPANY for the right to incorporate
LICENSED PRODUCTS in its own drug delivery system(s) and for any one or more of
the rights to market, distribute, sell, use, and/or transfer the resulting
combination, or c) any non-AFFILIATE entity which agrees to compensate (either
in cash or non-cash) COMPANY for the right to attach its own biologically active
agent(s) to LICENSED PRODUCTS and for any one or more of the rights to market,
distribute, sell, use, and/or transfer the resulting combination. Any CORPORATE
PARTNER, as defined in this paragraph, that also receives a sublicense of the
PATENT RIGHTS shall also be considered a SUBLICENSEE

      1.4 "CORPORATE PARTNER INCOME" shall mean any payments that COMPANY or an
AFFILIATE receives from a CORPORATE PARTNER in consideration for rights to
market, distribute, sell, use and/or transfer LICENSED PRODUCTS and/or LICENSED
PROCESSES, including without limitation license fees, milestone payments other
than those defined under MILESTONE PAYMENTS, license maintenance fees, and other
payments, but specifically excluding MILESTONE PAYMENTS, royalties on NET SALES,
payments received for the license or sublicense of any intellectual property
other than the PATENT RIGHTS, reimbursement for patent and other expenses
incurred or to be incurred in behalf of the CORPORATE PARTNER, amounts received
by COMPANY from a CORPORATE PARTNER for equity at FAIR MARKET VALUE, debt at
fair market value, or payment for COMPANY's actual costs, without mark up, for
each of research and development, equipment, supplies, and products or services
purchased from COMPANY.

      1.5 "EXCLUSIVE PERIOD" shall mean the period of time set forth in Section
2.2.

      1.6 "FAIR MARKET VALUE" shall mean the closing price on the public
exchange for a share of Common Stock in COMPANY or in the event that COMPANY's
stock is not publicly traded, the highest price per share that the COMPANY could
obtain from a willing buyer (not a current employee or director) for shares of
Common Stock sold by the COMPANY, from

                                       2
<PAGE>
authorized but unissued shares, as determined in good faith by the Board of
Directors of the COMPANY, unless the COMPANY shall become subject to a merger,
acquisition or other consolidation pursuant to which the COMPANY is not the
surviving party, in which case the current fair market value of a share of
Common Stock shall be deemed to be the value received by the holders of the
COMPANY's Common Stock for each share of Common Stock pursuant to the COMPANY's
acquisition.

      1.7 "FIELD" shall mean human therapeutics for the treatment of
neurological disorders and conditions, which shall include disorders and
conditions pertaining to the central nervous, peripheral nervous, autonomic
nervous, and neuromuscular systems.

      1.8 "IMPROVEMENT" shall mean any patentable invention, or group of
patentable inventions that are: (a) not included in the PATENT RIGHTS; (b)
dominated by a VALID CLAIM of the PATENT RIGHTS; (c) conceived or reduced to
practice under M.I.T. research programs in which Professor Ram Sasisekharan is
the principal investigator; and (d) disclosed to the M.I.T. Technology Licensing
Office within one (1) year of the EFFECTIVE DATE of this Agreement.

      1.9 "KNOW-HOW" shall mean any M.I.T.-owned technical information,
know-how, procedures, or methods known to Dr. Ram Sasisekharan that may be
necessary or useful in the development, manufacture, use, sale, lease or import
of LICENSED PRODUCTS or LICENSED PROCESSES and which is acquired by the COMPANY
during the first year of the TERM.

      1.10  "LICENSED PRODUCT" shall mean any product or part thereof that:
            (i)   absent the license granted hereunder, would infringe one
or more VALID CLAIMS of the PATENT RIGHTS; or
            (ii) is manufactured by using a LICENSED PROCESS or that, when used,
practices a LICENSED PROCESS.

      1.11 "LICENSED PROCESS" shall mean any process that, absent the license
granted hereunder, would infringe one or more VALID CLAIMS of the PATENT RIGHTS
or which uses a LICENSED PRODUCT.

      1.12 "MILESTONE PAYMENT" shall mean a payment to COMPANY or AFFILIATE from
a CORPORATE PARTNER or SUBLICENSEE due upon achievement of an agreed upon
technical, business, or regulatory milestone pertaining to the research,
development or commercialization of LICENSED PRODUCTS or LICENSED PROCESSES.
Illustrative examples of such milestones include, but are not limited to: using
LICENSED PRODUCTS to deliver a certain drug in a living animal, delivery of a
sample LICENSED PRODUCT customized to the requirements of the CORPORATE PARTNER
or SUBLICENSEE, obtaining regulatory approval for a LICENSED PRODUCT. Payments
received by COMPANY for the purchase or sale of debt up to and at fair market
value or of equity in COMPANY at a price up to and including the FAIR MARKET
VALUE are excluded from this definition. The amount of such payment which
exceeds the FAIR MARKET VALUE is included in this definition. Bona fide payments
to COMPANY or AFFILIATE from a CORPORATE PARTNER or SUBLICENSEE that are
expressly intended to fund or pay for equipment, supplies, research and
development, products, services, patent expenses or other expenses incurred or
to be incurred in behalf of that CORPORATE PARTNER or SUBLICENSEE are excluded
from this definition.

                                       3
<PAGE>
Bona fide payments to COMPANY or AFFILIATES from a CORPORATE PARTNER or
SUBLICENSEE for rights other than those licensed hereunder are excluded from
this definition. (documentation of all payments described in this paragraph to
be provided as described in Section 5.2(viii)).

      1.13 "NET SALES" shall mean the gross amount billed by COMPANY and its
AFFILIATES and SUBLICENSEES for LICENSED PRODUCTS and LICENSED PROCESSES, less
the following:

            (i) customary trade, quantity, or cash discounts to the extent
actually allowed and taken;

            (ii) amounts repaid or credited by reason of rejection or
return;

            (iii) to the extent separately stated on purchase orders, invoices,
or other documents of sale, any taxes or other governmental charges levied on
the production, sale, transportation, delivery, or use of a LICENSED PRODUCT or
LICENSED PROCESS which is paid by or on behalf of COMPANY; and

            (iv) outbound transportation and packing costs prepaid or allowed
and costs of insurance in transit.

            (v) unpaid balances on amounts so billed for LICENSED PRODUCTS and
LICENSED PROCESSES that have not been paid, not withstanding COMPANY's
reasonable efforts of collection, within 120 days of the date such balances were
due, and provided that unpaid balances do not exceed [**] of NET SALES for that
REPORTING PERIOD.

            No deductions shall be made for commissions paid to individuals
whether they be with independent sales agencies or regularly employed by COMPANY
and on its payroll, or for cost of collections. NET SALES shall occur on the
date of billing for a LICENSED PRODUCT or LICENSED PROCESS. If a LICENSED
PRODUCT or a LICENSED PROCESS is distributed at a discounted price that is
substantially lower than the customary price charged by COMPANY, or distributed
for non-cash consideration (whether or not at a discount), NET SALES shall be
calculated based on the non-discounted amount of the LICENSED PRODUCT or
LICENSED PROCESS charged or customarily charged to an independent third party
during the same REPORTING PERIOD or, in the absence of such sales, on the fair
market value of the LICENSED PRODUCT or LICENSED PROCESS, provided, however,
that M.I.T. agrees that COMPANY may distribute a commercially reasonable
quantity (not to exceed [**] of the total NET SALES for that REPORTING PERIOD)
of LICENSED PRODUCTS at a discounted price, or at no cost to the recipients of
such LICENSED PRODUCTS for development, marketing, and sales purposes which
shall not be included in the NET SALES calculation at fair market value..

            Non-monetary consideration shall not be accepted by COMPANY, any
AFFILIATE, or any SUBLICENSEE for any LICENSED PRODUCTS or LICENSED PROCESSES
without the prior written consent of M.I.T.

            In the event that a LICENSED PROCESS is provided or a LICENSED
PRODUCT is sold in combination with another process or product which is not a
LICENSED PROCESS or LICENSED PRODUCT, NET SALES shall mean the amount billed by
COMPANY or its AFFILIATES and SUBLICENSEES on sales of the combination process
or product less the deductions set forth above, multiplied by a proration factor
that is determined as follows:

      If all components of the combination process or product were sold
      separately during the same or immediately preceding year, the proration
      factor shall be determined by the formula [A / (A+B)], where A is the
      aggregate gross sales price of all LICENSED PROCESS or LICENSED PRODUCT
      components during such

                                       4
<PAGE>
      period when sold separately from the other essential functional
      components, and B is the aggregate gross sales price of the other
      essential functional components during such period when sold separately
      from the LICENSED PROCESS or LICENSED PRODUCT components; or If all
      components of the combination process or product were not sold separately
      during the same or immediately preceding year, the proration factor shall
      be determined by the formula [C / (C+D)], where C is the value of the
      LICENSED PROCESS or LICENSED PRODUCT components and D is the value of the
      other essential functional components, with such value being determined in
      good faith by the parties.

      1.14 "PATENT EXPENSES" shall mean all fees and costs, including attorneys
fees, relating to the filing, prosecution and maintenance of the PATENT RIGHTS.

      1.15  "PATENT RIGHTS" shall mean:

            (a) the United States and international patents listed on Appendix
A;

            (b) the United States and international patent applications and/or
provisional applications listed on Appendix A and the resulting patents;

            (c) any patent applications resulting from the provisional
applications listed on Appendix A, and any divisionals, continuations,
continuation-in-part applications, and continued prosecution applications (and
their relevant international equivalents) of the patent applications listed on
Appendix A and of such patent applications that result from the provisional
applications listed on Appendix A, to the extent the claims are directed to
subject matter specifically described in the patent applications listed on
Appendix A, and the resulting patents;

            (d) any patents resulting from reissues, reexaminations, or
extensions (and their relevant international equivalents) of the patents
described in (a), (b), and (c) above; and

            (e) international (non-United States) patent applications and
provisional applications filed after the EFFECTIVE DATE and the relevant
international equivalents to divisionals, continuations, continuation-in-part
applications and continued prosecution applications of the patent applications
to the extent the claims are directed to subject matter specifically described
in the patents or patent applications referred to in (a), (b), (c), and (d)
above, and the resulting patents.

      1.16 "REPORTING PERIOD" shall begin on the first day of each calendar
quarter and end on the last day of such calendar quarter.

      1.17 "SUBLICENSE INCOME" shall mean any payments that COMPANY receives
from a SUBLICENSEE in consideration of the sublicense of the rights granted
COMPANY under Section 2.1, including without limitation license fees, milestone
payments other than those defined under MILESTONE PAYMENTS, license maintenance
fees, and other payments, but specifically excluding MILESTONE PAYMENTS,
royalties on NET SALES, payments received for the license or sublicense of any
intellectual property other than the PATENT RIGHTS, payments received by COMPANY
from a SUBLICENSEE for the purchase or sale of debt at fair market value or of
equity at FAIR MARKET VALUE, reimbursement for patent expenses or payment for
COMPANY's actual costs, without mark up for each of research and development,
equipment, supplies, and products or services purchased from COMPANY.

                                       5
<PAGE>
      1.18 "SUBLICENSEE" shall mean any non-AFFILIATE sublicensee of the rights
granted COMPANY under Section 2.1.

      1.19 "TANGIBLE PROPERTY" shall mean shall mean the specific biological
and/or chemical material as identified in Appendix C. M.I.T. retains ownership
of any TANGIBLE PROPERTY.

      1.20 "TERM" shall mean the term of this Agreement, which shall commence on
the EFFECTIVE DATE and shall remain in effect until the expiration or
abandonment of the last remaining VALID CLAIM of any issued patents and filed
patent applications within the PATENT RIGHTS, unless earlier terminated in
accordance with the provisions of this Agreement, in which case the TERM shall
terminate upon the effective date of such termination.

      1.21  "TERRITORY" shall mean worldwide.

      1.22 "VALID CLAIM" shall mean a either (a) a claim of an issued patent
within the PATENT RIGHTS that has not been held invalid by an administrative
agency or court of competent jurisdiction in any unappealed or unappealable
decision or (b) a claim of a pending application that has not been abandoned or
finally rejected without the possibility of appeal or refilling. The invalidity
of a particular claim in one or more countries shall not invalidate such claim
in the remaining countries of the TERRITORY.

                               2. GRANT OF RIGHTS.

      2.1  License Grants.  Subject to the terms of this Agreement, M.I.T.
hereby grants to COMPANY and its AFFILIATES for the TERM

            (a) a royalty-bearing license under the PATENT RIGHTS to develop,
make, have made, use, sell, offer to sell, lease, and import LICENSED PRODUCTS
in the FIELD in the TERRITORY and to develop and perform LICENSED PROCESSES in
the FIELD in the TERRITORY;

            (b) a royalty-bearing license to use the TANGIBLE PROPERTY to
develop, make, have made, use, sell, offer to sell, lease and import LICENSED
PRODUCTS in the FIELD in the TERRITORY and to develop and perform LICENSED
PROCESSES in the FIELD in the TERRITORY.

      2.2 Exclusivity. In order to establish an exclusive period for COMPANY,
M.I.T. agrees that it shall not grant any other license to develop, make, have
made, use, sell, offer to sell, lease and import LICENSED PRODUCTS in the FIELD
in the TERRITORY or to perform LICENSED PROCESSES in the FIELD in the TERRITORY
during the TERM, unless sooner terminated as provided in this Agreement.

      2.3 Exclusive Option to IMPROVEMENTS. Provided that an IMPROVEMENT is not
encumbered by an agreement with a third party that would preclude so adding
them, M.I.T. hereby grants to COMPANY an exclusive option to add IMPROVEMENTS to
the PATENT RIGHTS in the FIELD for which exclusive rights are granted in Section
2.2, for sixty (60) days after COMPANY has been notified of the existence of
each such IMPROVEMENT (an "Option Period"). M.I.T. shall notify COMPANY in
writing of any IMPROVEMENTS and the fee, if

                                       6
<PAGE>
any, of up to [**] as determined by M.I.T. commensurate with the value of the
IMPROVEMENT, to add such IMPROVEMENT to the PATENT RIGHTS. At the same time,
M.I.T. shall furnish COMPANY a copy of the invention disclosure and any related
patent applications, which shall be kept confidential under the terms of Section
5.5 of this Agreement. COMPANY may exercise its option to add such IMPROVEMENT
to the PATENT RIGHTS by providing M.I.T., within the relevant Option Period,
with written notification of COMPANY's desire to so add the IMPROVEMENT to the
PATENT RIGHTS and by paying M.I.T. the requested fee for each IMPROVEMENT so
added. Upon COMPANY's exercise of such right, such IMPROVEMENT shall be added to
the PATENT RIGHTS and Appendix A hereto shall be deemed to have been amended to
add the invention disclosure (and any related patent applications) covering such
IMPROVEMENT. M.I.T. shall provide COMPANY with an updated Appendix A for its
records within thirty (30) days of M.I.T.'s receipt of the requested fee. Until
the earlier of either (a) COMPANY's failure to exercise its right to add an
IMPROVEMENT to the PATENT RIGHTS within the relevant Option Period or (b)
COMPANY written notification to M.I.T. that it is not interested in adding such
IMPROVEMENT to the PATENT RIGHTS, M.I.T. shall not offer a license to such
IMPROVEMENT to any third party, except to the extent M.I.T. is obligated under
an agreement to so offer such IMPROVEMENT to a third party.

      2.4 Transfer of TANGIBLE PROPERTY to Third Parties. COMPANY and its
AFFILIATES may not transfer the TANGIBLE PROPERTY to any third parties, except
COMPANY may transfer the TANGIBLE PROPERTY to SUBLICENSEES under the terms of
Article 2.5 and may transfer the TANGIBLE PROPERTY to third parties for the sole
purpose of either developing a manufacturing process of a LICENSED PRODUCT or
for the manufacture of a LICENSED PRODUCT, provided that such third party agrees
to not to further transfer the TANGIBLE PROPERTY and upon the end of its
relationship with COMPANY, destroys the TANGIBLE PROPERTY per Article 12.4(c).

      2.5 Sublicenses. COMPANY shall have the right to grant sublicenses of its
rights under Section 2.1 only during the EXCLUSIVE PERIOD. Such sublicenses may
extend past the expiration date of the EXCLUSIVE PERIOD, but any exclusivity of
such sublicense shall expire upon the expiration of the EXCLUSIVE PERIOD.
COMPANY shall incorporate terms and conditions into its sublicense agreements
sufficient to enable COMPANY to comply with this Agreement. COMPANY shall
promptly furnish M.I.T. with copies of those portions related to the PATENT
RIGHTS of an executed version of any sublicense agreement sufficient to
demonstrate COMPANY's compliance with the terms of this agreement. Upon
termination of this Agreement for any reason, any SUBLICENSEE not then in
default shall have the right to seek a license from M.I.T. M.I.T. agrees to
negotiate such licenses in good faith under reasonable terms and conditions to
be no less favorable as a whole than those granted to SUBLICENSEE by COMPANY.

      2.6  U.S. Manufacturing.  COMPANY agrees that any LICENSED PRODUCTS
used or sold in the United States will be manufactured substantially in
the United States to the extent required by 35 U.S.C. 204.

                                       7
<PAGE>
      2.7  Retained Rights.

            (a) M.I.T. M.I.T. retains the right to practice under the PATENT
RIGHTS for research, teaching, and educational purposes.

            (b) Federal Government. COMPANY acknowledges that the U.S. federal
government retains a royalty-free, non-exclusive, non-transferable license to
practice any government-funded invention claimed in any PATENT RIGHTS as set
forth in 35 U.S.C.Sections 201-211, and the regulations promulgated thereunder,
as amended, or any successor statutes or regulations.

      2.8 No Additional Rights. Nothing in this Agreement shall be construed to
confer any rights upon COMPANY by implication, estoppel, or otherwise as to any
technology or patent rights of M.I.T. or any other entity other than the PATENT
RIGHTS and IMPROVEMENTS, regardless of whether such technology or patent rights
shall be dominant or subordinate to any PATENT RIGHTS. COMPANY shall have no
obligations or liabilities to M.I.T. for any future use of any KNOW-HOW that
COMPANY has or will acquire.

                        3. COMPANY DILIGENCE OBLIGATIONS.

      3.1 Diligence Requirements. COMPANY shall use commercially reasonable
diligent efforts, or shall require its AFFILIATES and SUBLICENSEES to use
commercially reasonable diligent efforts, to develop one or more LICENSED
PRODUCTS or LICENSED PROCESSES and to introduce LICENSED PRODUCTS or LICENSED
PROCESSES into the commercial market; thereafter, COMPANY shall use commercially
reasonable diligent efforts to make or shall require its AFFILIATES or
SUBLICENSEES to use commercially reasonable diligent efforts to make one or more
LICENSED PRODUCTS or LICENSED PROCESSES reasonably available to the public.
Specifically, COMPANY or AFFILIATE or SUBLICENSEE shall fulfill the following
obligations:

            (a) Within [**] after the EFFECTIVE DATE, COMPANY shall furnish
M.I.T. with a written research and development plan describing the major tasks
to be achieved in order to bring to market a LICENSED PRODUCT or a LICENSED
PROCESS, specifying the number of staff and other resources to be devoted to
such commercialization effort.

            (b) Within [**], COMPANY shall furnish M.I.T. with a written report
(consistent with Section 5.1(a)) on the progress of its efforts during the
immediately preceding calendar year to develop and commercialize LICENSED
PRODUCTS or LICENSED PROCESSES. The report shall also contain a discussion of
intended efforts and sales projections for the year in which the report is
submitted.

            (c) COMPANY shall permit an in-plant inspection by M.I.T. on or
before December 31, 2002, during COMPANY's normal business hours and with at
least ten (10) days prior written notice from M.I.T., and thereafter permit
in-plant inspections by M.I.T. during such hours and with such notice at regular
intervals with at least twelve (12) months between each such inspection.

                                       8
<PAGE>
            (d) COMPANY shall designate no less than two (2) full-time
equivalent personnel ("FTE"s) towards the development of LICENSED PRODUCTS from
the EFFECTIVE DATE until December 31, 2003.

            (e) COMPANY shall designate no less than four (4) FTEs towards the
development of LICENSED PRODUCTS beginning January 1, 2004 and ending upon the
first commercial sale of a therapeutic LICENSED PRODUCT.

            (f) COMPANY shall cause the development of LICENSED PRODUCTS and
LICENSED PROCESSES to be managed and directed by a COMPANY employee or
consultant whose credentials shall include, but are not limited to, more than
five (5+) years in clinical and pre-clinical stroke recovery research including
administration of animal and clinical trials of FGF molecules similar to the one
disclosed under M.I.T. Case No. 9265.

            (g) COMPANY shall have begun all toxicology studies related to
LICENSED PRODUCTS and/or LICENSED PROCESSES by December 31, 2004.

            (h) COMPANY shall file for an IND covering a LICENSED PRODUCT and/or
a LICENSED PROCESS by December 31, 2006.

            (i) COMPANY shall file for a BLA covering a LICENSED PRODUCT and/or
a LICENSED PROCESS by December 31, 2009.

            (j) COMPANY shall make a first commercial sale of a LICENSED PRODUCT
and/or a first commercial performance of a LICENSED PROCESS on or before June
30, 2010.

            (k) COMPANY shall make NET SALES of at least [**] per calendar year
within two (2) years of the first commercial sale of a LICENSED PRODUCT.

            The foregoing not withstanding, upon COMPANY's written request and
M.I.T.'s consent, such consent not to be unreasonably withheld or delayed, the
time periods specified in this Section 3.1 shall be extended to mutually
acceptable dates by amendment to this agreement if such an extension is
supported in writing by evidence of technical difficulties or delays that could
not have been reasonably avoided and the parties could not have reasonably
anticipated as of the EFFECTIVE DATE.

            In the event that M.I.T. determines that COMPANY (or an AFFILIATE or
SUBLICENSEE) has not fulfilled its obligations under Section 3.1(a-j), taking
into account any agreed upon extensions of the term periods therein, M.I.T.
shall furnish Company with written notice of such determination, which shall
state the consequences of such failure, including termination of the license.
Within sixty (60) days after receipt of such notice, COMPANY shall either (i)
fulfill the relevant obligation or, (ii) at M.I.T.'s sole discretion, negotiate
an acceptable schedule of revised diligence obligations, failing which M.I.T.
may treat such failure as a material breach in accordance with Section 12.3(b).

                                       9
<PAGE>
                         4. ROYALTIES AND PAYMENT TERMS.

      4.1  Consideration for Grant of Rights.

            (a) License Issue Fee and Patent Cost Reimbursement. COMPANY shall
pay to M.I.T. on the EFFECTIVE DATE a license issue fee of Fifty Thousand
dollars ($50,000.00), less the Ten Thousand dollars ($10,000) that COMPANY has
previously paid to M.I.T. in Option Fees, and, in accordance with Section 6.3,
shall reimburse M.I.T. for its actual expenses incurred as of the EFFECTIVE DATE
in connection with obtaining the PATENT RIGHTS. These payments are
nonrefundable.

            (b) License Maintenance Fees. COMPANY shall pay to M.I.T. the
following license maintenance fees on the dates set forth below:

<TABLE>
<S>                                      <C>
                  June 1, 2003           [**]
                  June 1, 2004           [**]
                  June 1, 2005           [**]
                  June 1, 2006           [**]
                  June 1, 2007           [**]
                  June 1, 2008           [**]
                  June 1, 2009           [**]
                  June 1, 2010           [**]
                  and each June 1 of
                  every year thereafter  [**]
</TABLE>

                  This annual license maintenance fee is [**]; however, the
license maintenance fee shall be [**] earned during the same calendar year, if
any. License maintenance fees paid in excess of running royalties due in such
calendar year [**] amounts due for future years.

            (c) Milestone Payments: COMPANY shall pay to M.I.T. the following
amounts upon achievement of certain product development milestones as set forth
below:

                  (i)   Upon the FDA's acceptance of the first IND application
                        by COMPANY covering a LICENSED PRODUCT or a LICENSED
                        PROCESS: [**].

                  (ii)  Upon COMPANY's filing of the first BLA covering a
                        LICENSED PRODUCT or LICENSED PROCESS: [**].

                  (iii) Upon the FDA's approval of COMPANY's first BLA covering
                        a LICENSED PRODUCT or LICENSED PROCESS:
                        [**]

                  These product development milestones are[**]; however, a
milestone shall be [**], if any. Product development milestones paid in excess
of running royalties due in such calendar year [**] amounts due for future
years.

            (d) Running Royalties. COMPANY shall pay to M.I.T. a running royalty
of [**] of NET SALES by COMPANY, AFFILIATES and SUBLICENSEES. Running royalties
shall be payable for each REPORTING PERIOD and shall be due to M.I.T. within
sixty (60) days of the end of each REPORTING PERIOD. Royalty obligations with
respect to each

                                       10
<PAGE>
LICENSED PROCESS and LICENSED PRODUCT shall terminate on a country-by-country
basis upon the expiration of the last-to-expire VALID CLAIM, which covers each
LICENSED PROCESS and LICENSED PRODUCT in each country.

            (e) Sharing of Other Income. COMPANY shall pay M.I.T. a total of
[**] of all SUBLICENSE INCOME, CORPORATE PARTNER INCOME and MILESTONE PAYMENTS
received by COMPANY or AFFILIATES, excluding running royalties on NET SALES of
SUBLICENSEES. For the avoidance of doubt, any payment made to COMPANY by a
SUBLICENSEE or CORPORATE PARTNER shall only be counted (if at all) towards only
one of SUBLICENSE INCOME, CORPORATE PARTNER INCOME or MILESTONE PAYMENTS and
shall not be counted towards two or more of the preceding figures such that
COMPANY shall owe M.I.T. only [**] payment on any such payment by a SUBLICENSEE
or CORPORATE PARTNER. Such amount shall be payable for each REPORTING PERIOD and
shall be due to M.I.T. within sixty (60) days of the end of each REPORTING
PERIOD.

            (f) No Multiple Royalties. If the manufacture, use, lease, or sale
of any LICENSED PRODUCT or the performance of any LICENSED PROCESS is covered by
more than one of the PATENT RIGHTS, multiple royalties shall not be due.

            (g) Third Party Royalties. In the event that COMPANY is legally
required to make royalty payments to one or more third parties whose patent
rights dominate the PATENT RIGHTS, in order to develop, make, have made, use,
sell, offer to sell, lease, and import LICENSED PRODUCTS or to perform any
LICENSED PROCESSES, COMPANY may offset a total of [**] of such third-party
payments against any royalty payments that are due to M.I.T. in the same
REPORTING PERIOD; provided, however that in no event shall the royalty payments
under Section 4.1(d) when aggregated with any other offsets and credits allowed
under this Agreement, be reduced by more than [**] in any REPORTING PERIOD.

      4.2  Payments.

            (a) Method of Payment. All payments under this Agreement should be
made payable to "Massachusetts Institute of Technology" and sent to the address
identified in Section 1.1. Each payment should reference this Agreement and
identify the obligation under this Agreement that the payment satisfies.

            (b) Payments in U.S. Dollars. All payments due under this Agreement
shall be drawn on a United States bank and shall be payable in United States
dollars. Conversion of foreign currency to U.S. dollars shall be made at the
conversion rate existing in the United States (as reported in the Wall Street
Journal) on the last working day of the calendar quarter of the applicable
REPORTING PERIOD. Such payments shall be without deduction of exchange,
collection, or other charges, and, specifically, without deduction of
withholding or similar taxes or other government imposed fees or taxes, except
as permitted in the definition of NET SALES.

            (c) Blocked Payments. If by law, regulation, or fiscal policy of a
particular country, conversion into United States dollars or transfer of funds
of a convertible currency to the United States is restricted or forbidden
("Blocked Payments"), COMPANY shall give M.I.T. prompt notice in writing and
shall pay the Blocked Payments through such means or methods as are lawful in
such country as M.I.T. may reasonably designate. Failing the designation by
M.I.T.

                                       11
<PAGE>
of such lawful means or methods within thirty (30) days after such notice is
given to M.I.T., COMPANY shall deposit such Blocked Payments in local currency
to the credit of M.I.T. in a recognized banking institution selected by COMPANY
and identified in a written notice to M.I.T. by COMPANY, and such deposit shall
fulfill all obligations of COMPANY to M.IT. with respect to such Blocked
Payments. So long as COMPANY satisfies the provisions of this Section 4.2(c),
COMPANY shall not be considered to have violated any of its payment obligations
hereunder with respect to any Blocked Payments.

            (d) Late Payments. Any payments by COMPANY that are not paid on or
before the date such payments are due under this Agreement shall bear interest,
to the extent permitted by law, at two percentage points above the Prime Rate of
interest as reported in the Wall Street Journal on the date payment is due.

                          5. REPORTS AND RECORDS.

      5.1  Frequency of Reports.

            (a) Before First Commercial Sale. Prior to the first commercial sale
of any LICENSED PRODUCT or first commercial performance of any LICENSED PROCESS,
COMPANY shall deliver reports to M.I.T. annually, within sixty (60) days of the
end of each calendar year, containing information concerning the immediately
preceding calendar year, as further described in Section 5.2.

            (b) Upon First Commercial Sale of a LICENSED PRODUCT or Commercial
Performance of a LICENSED PROCESS. COMPANY shall report to M.I.T. the date of
first commercial sale of a LICENSED PRODUCT and the date of first commercial
performance of a LICENSED PROCESS within sixty (60) days of occurrence in each
country.

            (c) After First Commercial Sale. After the first commercial sale of
a LICENSED PRODUCT or first commercial performance of a LICENSED PROCESS,
COMPANY shall deliver reports to M.I.T. within sixty (60) days of the end of
each REPORTING PERIOD, containing information concerning the immediately
preceding REPORTING PERIOD, as further described in Section 5.2.

      5.2  Content of Reports and Payments.  Each report delivered by
COMPANY to M.I.T. shall contain at least the following information for the
immediately preceding REPORTING PERIOD:

            (i) the number of LICENSED PRODUCTS sold, leased or distributed by
COMPANY, its AFFILIATES and SUBLICENSEES to independent third parties in each
country, and, if applicable, the number of LICENSED PRODUCTS used by COMPANY,
its AFFILIATES and SUBLICENSEES in the provision of services in each country;

            (ii) a description of LICENSED PROCESSES performed by COMPANY, its
AFFILIATES and SUBLICENSEES in each country as may be pertinent to a royalty
accounting hereunder;

                                       12
<PAGE>
            (iii) the gross price charged by COMPANY, its AFFILIATES and
SUBLICENSEES for each LICENSED PRODUCT and, if applicable, the gross price
charged for each LICENSED PRODUCT used to provide services in each country; and
the gross price charged for each LICENSED PROCESS performed by COMPANY, its
AFFILIATES and SUBLICENSEES in each country;

            (iv) calculation of NET SALES for the applicable REPORTING PERIOD in
each country, including a listing of applicable deductions;

            (v) total royalty payable on NET SALES in U.S. dollars, together
with the exchange rates used for conversion;

            (vi) the amount of SUBLICENSE INCOME received by COMPANY from each
SUBLICENSEE and the amount due to M.I.T. from such SUBLICENSE INCOME, including
an itemized breakdown of the sources of income comprising the SUBLICENSE INCOME;
and

            (vii) the amount of CORPORATE PARTNER INCOME received by COMPANY
from each CORPORATE PARTNER and the amount due to M.I.T. from such CORPORATE
PARTNER INCOME, including an itemized breakdown of the sources of income
comprising the CORPORATE PARTNER INCOME; and

            (viii) the amount of MILESTONE PAYMENTS received by COMPANY and the
amount due to M.I.T. from such MILESTONE PAYMENTS, including an itemized
breakdown of the sources of income comprising the MILESTONE PAYMENTS; and

            (ix) the number of sublicenses entered into for the PATENT RIGHTS,
LICENSED PRODUCTS and/or LICENSED PROCESSES.

            (x) the number of CORPORATE PARTNER agreements entered into for the
REPORTING PERIOD.

      If no amounts are due to M.I.T. for any REPORTING PERIOD, the report
shall so state.

      5.3 Financial Statements. On or before the ninetieth (90th) day following
the close of COMPANY's fiscal year, COMPANY shall provide M.I.T. with COMPANY's
financial statements for the preceding fiscal year including, at a minimum, a
balance sheet and an income statement, certified by COMPANY's treasurer or chief
financial officer or by an independent auditor.

      5.4 Records. COMPANY shall maintain, and shall require its AFFILIATES and
SUBLICENSEES to maintain, complete and accurate records relating to the rights
and obligations under this Agreement and any amounts payable to M.I.T. in
relation to this Agreement, which records shall contain sufficient information
to permit M.I.T. to confirm the accuracy of any reports delivered to M.I.T. and
compliance in other respects with this Agreement. The relevant party shall
retain such records for at least five (5) years following the end of the
calendar year to which they pertain, during which time M.I.T. shall have the
right to appoint a certified public accountant reasonably acceptable to COMPANY
to inspect such records, at M.I.T.'s expense, during COMPANY's normal business
hours and upon reasonable

                                       13
<PAGE>
notice to COMPANY for the sole purpose of verifying any reports and payments
made or compliance in other respects under this Agreement. In the event that any
audit performed under this Section reveals an underpayment in excess of five
percent (5%), COMPANY shall bear the full cost of such audit and shall remit any
amounts due to M.I.T. within thirty (30) days of receiving notice thereof from
M.I.T.

      5.5 Information Exchange. During the TERM, COMPANY and M.I.T. are likely
to exchange information relating to the PATENT RIGHTS and their commercial
exploitation by COMPANY. The following provisions are intended to protect the
confidential or proprietary information of each party.

            (a) Confidential Information. "Confidential Information" shall mean
any confidential or proprietary information furnished by one party (the
"Disclosing Party") to the other party (the "Receiving Party") in connection
with this Agreement, provided that such information is specifically designated
in writing as confidential. Such Confidential Information shall include, without
limitation, any information relating to the PATENT RIGHTS and the records and
reports provided by COMPANY to M.I.T. pursuant to Sections 5.1 and 5.2.
Confidential Information that is disclosed in writing shall be marked with a
legend indicating its confidential status (such as "Confidential" or
"Proprietary"). Confidential Information that is disclosed orally or visually
shall be documented in a written notice prepared by the Disclosing Party and
delivered to the Receiving Party within thirty (30) days of the date of
disclosure; such notice shall summarize the Confidential Information disclosed
to the Receiving Party and reference the time and place of disclosure.

            (b) Obligations. During the period of this Agreement and for a
period of three (3) years thereafter,, the Receiving Party shall (i) maintain
Confidential Information of the Disclosing Party in strict confidence, except
that the Receiving Party may disclose or permit the disclosure of any
Confidential Information to its directors, officers, employees, consultants, and
advisors who are obligated to maintain the confidential nature of such
Confidential Information and who need to know such Confidential Information for
the purposes of this Agreement; (ii) use such Confidential Information solely
for the purposes of this Agreement; and (iii) allow its trustees or directors,
officers, employees, consultants, and advisors to reproduce the Confidential
Information only to the extent necessary for the purposes of this Agreement,
with all such reproductions being considered Confidential Information.

            (c) Exceptions. The obligations of the Receiving Party under Section
5.5(b) above shall not apply to the extent that the Receiving Party can
demonstrate that certain Confidential Information (i) was in the public domain
prior to the time of its disclosure under this Agreement; (ii) entered the
public domain after the time of its disclosure under this Agreement through
means other than an unauthorized disclosure resulting from an act or omission by
the Receiving Party; (iii) was independently developed or discovered by the
Receiving Party without use of the Confidential Information; (iv) is or was
disclosed to the Receiving Party at any time, whether prior to or after the time
of its disclosure under this Agreement, by a third party having no fiduciary
relationship with the Disclosing Party and having no obligation of
confidentiality with respect to such Confidential Information; or (v) is
required to be disclosed to comply with applicable laws or regulations, or with
a court or administrative order, provided that the Disclosing Party receives
reasonable prior written notice of such

                                       14
<PAGE>
disclosure and the Receiving Party takes all reasonable actions to obtain
confidential treatment of such information and, if possible, to minimize the
extent of such disclosure.

            (d) Ownership and Return. The Receiving Party acknowledges that the
Disclosing Party (or any third party entrusting its own information to the
Disclosing Party) claims ownership of its Confidential Information in the
possession of the Receiving Party. Upon the expiration or termination of this
Agreement, and at the request of the Disclosing Party, the Receiving Party shall
return to the Disclosing Party all originals, copies, and summaries of
documents, materials, and other tangible manifestations of Confidential
Information in the possession or control of the Receiving Party, except that the
Receiving Party may retain one copy of the Confidential Information solely for
the purpose of monitoring its obligations under this Agreement.

            (e) Right to Injunctive Relief. The Receiving Party acknowledges
that disclosure or distribution of Confidential Information or use of
Confidential Information contrary to the terms of this Agreement may cause
irreparable harm to the Disclosing Party, for which damages at law may not be an
adequate remedy, and agrees that the provisions of this Agreement prohibiting
disclosure or distribution of the Confidential Information or use contrary to
the provisions hereof may be specifically enforced through injunctive relief by
a court of competent jurisdiction in addition to any and all other remedies
available at law or in equity.

                           6. PATENT PROSECUTION.

      6.1  Responsibility for PATENT RIGHTS.  M.I.T. shall prepare, file,
prosecute, and maintain all of the PATENT RIGHTS.  M.I.T. and its
appointed patent attorneys will use reasonable efforts to copy COMPANY on
all patent correspondence as follows: (a) documents received from any
patent office shall be provided to COMPANY promptly after receipt; (b) any
document to be filed in any patent office shall be provided in draft form
to COMPANY sufficiently prior to such document's filing to allow for
review and comment by COMPANY; and (c) documents filed with any patent
office shall be provided to COMPANY promptly after filing. COMPANY shall
have reasonable opportunities to advise M.I.T. and shall cooperate with
M.I.T. in such filing, prosecution and maintenance.

      6.2 International (non-United States) Filings. Appendix B is a list of
countries in which patent applications corresponding to the United States patent
applications listed in Appendix A shall be filed, prosecuted, and maintained.
Appendix B may be amended by mutual agreement of COMPANY and M.I.T.

      6.3 Payment of Expenses. Payment of all PATENT EXPENSES shall be the
responsibility of COMPANY, whether such amounts were incurred before or after
the EFFECTIVE DATE. As of August , 2002, M.I.T. has incurred approximately Eight
Thousand Dollars ($8000.00) for such patent-related fees and costs. COMPANY
shall reimburse all amounts due pursuant to this Section within thirty (30) days
of invoicing; late payments shall accrue interest pursuant to Section 4.2(c). In
all instances, M.I.T. shall pay the fees prescribed for large entities to the
United States Patent and Trademark Office.

                                       15
<PAGE>
      6.4 Third Party Share. If during the TERM, M.I.T. should grant an
exclusive license to any third party(ies) under the PATENT RIGHTS outside the
FIELD ("THIRD PARTY LICENSE"), COMPANY shall therefore be responsible for its
pro-rata share of PATENT EXPENSES during the term of such a THIRD PARTY LICENSE.
In addition, where reasonable, M.I.T. shall require such third party(ies) to pay
their pro-rata share of PATENT EXPENSES incurred before the Effective Date of
any THIRD PARTY LICENSE and any payment made under such a THIRD PARTY LICENSE
specifically towards PATENT EXPENSES already paid by COMPANY, will be credited
in full to the COMPANY.

      6.5 Abandonment. In the event that M.I.T. desires to abandon any patent or
patent application within the PATENT RIGHTS, M.I.T. shall provide COMPANY with
reasonable prior written notice of such intended abandonment or decline of
responsibility, and COMPANY shall have the right, at its expense, to prepare,
file, prosecute, and maintain the relevant PATENT RIGHTS.

                              7. INFRINGEMENT.

      7.1 Notification of Infringement. Each party agrees to provide written
notice to the other party promptly after becoming aware of any infringement of
the PATENT RIGHTS.

      7.2  Right to Prosecute Infringements.

            (a) COMPANY Right to Prosecute. So long as COMPANY remains the
exclusive licensee of the PATENT RIGHTS in the FIELD in the TERRITORY, COMPANY,
to the extent permitted by law, shall have the right, under its own control and
at its own expense, to prosecute any third party infringement of the PATENT
RIGHTS in the FIELD in the TERRITORY, subject to Sections 7.4 and 7.5. If
required by law, M.I.T. shall permit any action under this Section to be brought
in its name, including being joined as a party-plaintiff, provided that COMPANY
shall hold M.I.T. harmless from, and indemnify M.I.T. against, any costs,
expenses, or liability that M.I.T. incurs in connection with such action.

                  Prior to commencing any such action, COMPANY shall consult
with M.I.T. and shall consider the views of M.I.T. regarding the advisability of
the proposed action and its effect on the public interest, provided that any
decision to commence such an action shall be solely within the COMPANY's
discretion. COMPANY shall not enter into any settlement, consent judgment, or
other voluntary final disposition of any infringement action under this Section
without the prior written consent of M.I.T., such consent not to be unreasonably
withheld or delayed

            (b) M.I.T. Right to Prosecute. In the event that COMPANY is
unsuccessful in persuading the alleged infringer to desist or fails to have
initiated an infringement action within six (6) months after COMPANY first
becomes aware of the basis for such action, M.I.T. shall have the right, at its
sole discretion, to prosecute such infringement under its sole control and at
its sole expense, and any recovery obtained shall belong to M.I.T.

      7.3 Declaratory Judgment Actions. In the event that a declaratory judgment
action is brought against M.I.T. or COMPANY by a third party alleging
invalidity, unenforceability, or non-infringement of the PATENT RIGHTS, M.I.T.,
at its option, shall have the right within twenty (20) days after commencement
of such action to take over the sole defense of the action at

                                       16
<PAGE>
its own expense. If M.I.T. does not exercise this right, COMPANY may take over
the sole defense of the action at COMPANY's sole expense, subject to Sections
7.4 and 7.5. In either case, the non-controlling party shall have the right to
participate in, comment upon and make recommendations regarding the course of
the controlling party's defense of such declaratory judgment action, which
recommendations the controlling party. agrees to follow except to the extent
such recommendations would result, in M.I.T.'s reasonable determination, in an
unwarranted narrowing of the PATENT RIGHTS. The controlling party shall provide
to the non-controlling party each document or a draft thereof pertaining to the
declaratory judgment action, including but not limited to each communication
with opposing counsel, pleading, discovery request, or other court filing, as
follows: (a) documents received from the court or from opposing counsel shall be
provided to the non-controlling party promptly after receipt; and (b) for a
document to be served on opposing counsel or filed in court, a draft of such
document shall be provided to the non-controlling party sufficiently prior to
its filing, to allow for review and comment by the non-controlling party as
provided above.

      7.4 Offsets. COMPANY may offset a total of [**] of any expenses incurred
under Sections 7.2 and 7.3 against any payments due to M.I.T. under Article 4,
provided that in no event shall such payments under Article 4, when aggregated
with any other offsets and credits allowed under this Agreement toward such
payments, be reduced by more than [**] in any REPORTING PERIOD.

      7.5 Recovery. Any recovery obtained in an action brought by COMPANY under
Sections 7.2 or 7.3 shall be distributed as follows: (i) each party shall be
reimbursed for any expenses incurred in the action (including the amount of any
royalty or other payments withheld from M.I.T. as described in Section 7.4),
(ii) as to ordinary damages, COMPANY shall receive an amount equal to its lost
profits or a reasonable royalty on the infringing sales, or whichever measure of
damages the court shall have applied, and COMPANY shall pay to M.I.T. based upon
such amount a reasonable approximation of the royalties and other amounts that
COMPANY would have paid to M.I.T. if COMPANY had sold the infringing products,
processes and services rather than the infringer, and (iii) as to any award of
special or punitive damages, the COMPANY shall receive [**] and M.I.T. shall
receive [**] of any award.

      7.6 Cooperation. Each party agrees to cooperate in any action under this
Article which is controlled by the other party, provided that the controlling
party reimburses the cooperating party promptly for any costs and expenses
incurred by the cooperating party in connection with providing such assistance.

      7.7 Right to Sublicense. So long as COMPANY remains the exclusive licensee
of the PATENT RIGHTS in the FIELD in the TERRITORY, COMPANY shall have the sole
right to sublicense any alleged infringer in the FIELD in the TERRITORY for
future use of the PATENT RIGHTS in accordance with the terms and conditions of
this Agreement relating to sublicenses. Any upfront fees and other revenues
delivered to COMPANY pursuant to such sublicense shall be treated as set forth
in Article 4.

                     8. INDEMNIFICATION AND INSURANCE.

      8.1  Indemnification.

                                       17
<PAGE>
            (a) Indemnity. COMPANY shall indemnify, defend, and hold harmless
M.I.T. and its trustees, officers, faculty, students, employees, and agents and
their respective successors, heirs and assigns (the "Indemnitees"), against any
liability, damage, loss, or expense (including reasonable attorneys fees and
expenses) incurred by or imposed upon any of the Indemnitees in connection with
any claims, suits, actions, demands or judgments arising out of any theory of
liability (including without limitation actions in the form of tort, warranty,
or strict liability and regardless of whether such action has any factual basis)
concerning any product, process, or service that is made, used, sold, imported,
or performed pursuant to any right or license granted under this Agreement.

            (b) Procedures. The Indemnitees agree to provide COMPANY with prompt
written notice of any claim, suit, action, demand, or judgment for which
indemnification is sought under this Agreement. COMPANY agrees, at its own
expense, to provide attorneys selected by COMPANY and reasonably acceptable to
M.I.T. to defend against any such claim. The Indemnitees shall cooperate fully
with COMPANY in such defense and will permit COMPANY to conduct and control such
defense and the disposition of such claim, suit, or action (including all
decisions relative to litigation, appeal, and settlement); provided, however,
that any Indemnitee shall have the right to retain its own counsel, at the
expense of COMPANY, if representation of such Indemnitee by the counsel retained
by COMPANY would be inappropriate because of actual or potential differences in
the interests of such Indemnitee and any other party represented by such
counsel. COMPANY agrees to keep M.I.T. informed of the progress in the defense
and disposition of such claim and to consult with M.I.T. with regard to any
proposed settlement.

      8.2 Insurance. Prior to the first use of a LICENSED PRODUCT in humans,
COMPANY shall obtain and carry in full force and effect commercial general
liability insurance, including product liability and errors and omissions
insurance which shall protect COMPANY and Indemnitees with respect to events
covered by Section 8.1(a) above. Such insurance (i) shall list M.I.T. as an
additional insured thereunder, (ii) shall be endorsed to include product
liability coverage, and (iii) shall require thirty (30) days written notice to
be given to M.I.T. prior to any cancellation or material change thereof. The
limits of such insurance shall not be less than [**] per occurrence with an
aggregate of [**] for bodily injury including death; [**] per occurrence with an
aggregate of [**] for property damage; and [**] per occurrence with an aggregate
of [**] for errors and omissions. In the alternative, COMPANY may self-insure
subject to prior approval of M.I.T. If COMPANY does not self-insure, COMPANY
shall provide M.I.T. with Certificates of Insurance evidencing compliance with
this Section. COMPANY shall continue to maintain such insurance or
self-insurance after the expiration or termination of this Agreement during any
period in which COMPANY or any AFFILIATE or SUBLICENSEE continues (i) to make,
use, or sell a product that was a LICENSED PRODUCT under this Agreement or (ii)
to perform a service that was a LICENSED PROCESS under this Agreement, and
thereafter for a period of five (5) years.

                     9. REPRESENTATIONS AND WARRANTIES.

      9.1   By M.I.T.  M.I.T. warrants that:

            (a) as of the EFFECTIVE DATE, all inventors known to M.I.T.
are listed in APPENDIX A and have assigned their rights to U.S. Serial
Number 10/108,195 and PCT

                                       18
<PAGE>
Application Number US02/09517 to M.I.T. Damages on any breach of this warranty
by M.I.T. shall not exceed the amounts received under Article 4 hereunder.

            (b) if development of the PATENT RIGHTS was supported with United
States federal funds, M.I.T. has complied with the necessary federal regulations
to enable M.I.T. to retain title to the PATENT RIGHTS.

      9.2 No Other Representations or Warranties. EXCEPT AS MAY OTHERWISE BE
EXPRESSLY SET FORTH IN THIS AGREEMENT, M.I.T. MAKES NO REPRESENTATIONS OR
WARRANTIES OF ANY KIND CONCERNING THE PATENT RIGHTS, EXPRESS OR IMPLIED,
INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY, FITNESS FOR A
PARTICULAR PURPOSE, NONINFRINGEMENT, VALIDITY OF PATENT RIGHTS CLAIMS, WHETHER
ISSUED OR PENDING, AND THE ABSENCE OF LATENT OR OTHER DEFECTS, WHETHER OR NOT
DISCOVERABLE. Specifically, and not to limit the foregoing, M.I.T. makes no
warranty or representation (i) regarding the validity or scope of the PATENT
RIGHTS, and (ii) that the exploitation of the PATENT RIGHTS or any LICENSED
PRODUCT or LICENSED PROCESS will not infringe any patents or other intellectual
property rights of M.I.T. or of a third party.

      IN NO EVENT SHALL EITHER PARTY, AND THEIR TRUSTEES, DIRECTORS, OFFICERS,
EMPLOYEES AND AFFILIATES BE LIABLE FOR INCIDENTAL OR CONSEQUENTIAL DAMAGES OF
ANY KIND, INCLUDING ECONOMIC DAMAGES OR INJURY TO PROPERTY AND LOST PROFITS,
REGARDLESS OF WHETHER EITHER PARTY SHALL BE ADVISED, SHALL HAVE OTHER REASON TO
KNOW, OR IN FACT SHALL KNOW OF THE POSSIBILITY OF THE FOREGOING.

                                 10. ASSIGNMENT.

      This Agreement is personal to COMPANY and no rights or obligations may be
assigned by COMPANY without the prior written consent of M.I.T., except that
COMPANY may assign its rights and obligations under this Agreement without such
prior consent to an AFFILIATE or to a successor in connection with the merger,
consolidation, or sale of all or substantially all of its assets or that portion
of its business to which this Agreement relates; provided, however, that this
Agreement shall immediately terminate if the proposed assignee, including an
AFFILIATE, fails to agree in writing to be bound by the terms and conditions of
this Agreement on or before the effective date of the assignment.
      .

                        11. GENERAL COMPLIANCE WITH LAWS

      11.1 Compliance with Laws. COMPANY shall use reasonable commercial efforts
to comply with all commercially material local, state, federal, and
international laws and regulations relating to the development, manufacture,
use, and sale of LICENSED PRODUCTS and LICENSED PROCESSES.

      11.2 Export Control. COMPANY shall comply and shall require its AFFILIATES
and SUBLICENSEES to comply with all United States laws and regulations
controlling the export of certain commodities and technical data, including
without limitation all Export Administration Regulations of the United States
Department of Commerce. Among other things, these laws and

                                       19
<PAGE>
regulations prohibit or require a license for the export of certain types of
commodities and technical data to specified countries. COMPANY hereby gives
written assurance that it will comply with, and will require its AFFILIATES and
SUBLICENSEES to comply with, all United States export control laws and
regulations, that it bears sole responsibility for any violation of such laws
and regulations by itself or its AFFILIATES or SUBLICENSEES, and that it will
indemnify, defend, and hold M.I.T. harmless (in accordance with Section 8.1) for
the consequences of any such violation.

      11.3 Non-Use of M.I.T. Name. COMPANY shall not and shall require its
AFFILIATES and SUBLICENSEES not to use the name of "Massachusetts Institute of
Technology," "Lincoln Laboratory" or any variation, adaptation, or abbreviation
thereof, or of any of its trustees, officers, faculty, students, employees, or
agents, or any trademark owned by M.I.T., or any terms of this Agreement in any
promotional material or other public announcement or disclosure without the
prior written consent of M.I.T. The foregoing notwithstanding, without the
consent of M.I.T., COMPANY may state that it is licensed by M.I.T. under one or
more of the patents and/or patent applications comprising the PATENT RIGHTS.

      11.4 Marking of LICENSED PRODUCTS. To the extent commercially feasible and
consistent with prevailing business practices, COMPANY shall mark, and shall
cause its AFFILIATES and SUBLICENSEES to mark, all LICENSED PRODUCTS that are
manufactured or sold under this Agreement with the number of each issued patent
under the PATENT RIGHTS that applies to such LICENSED PRODUCT.

                                12. TERMINATION.

      12.1 Voluntary Termination by COMPANY. COMPANY shall have the right to
terminate this Agreement, for any reason, (i) upon at least six (6) months prior
written notice to M.I.T., such notice to state the date at least six (6) months
in the future upon which termination is to be effective, and (ii) upon payment
of all amounts due to M.I.T. through such termination effective date.

      12.2  Cessation of Business.  If COMPANY ceases to carry on its
business related to this Agreement, M.I.T. shall have the right to
terminate this Agreement immediately upon written notice to COMPANY.

      12.3  Termination for Default.

            (a) Nonpayment. In the event COMPANY fails to pay any amounts due
and payable to M.I.T. hereunder, and fails to make such payments within thirty
(30) days after receiving written notice of such failure, M.I.T. may terminate
this Agreement immediately upon written notice to COMPANY.

            (b) Material Breach. In the event either party commits a material
breach of its obligations under this Agreement, except for COMPANY's breach as
described in Section 12.3(a), and fails to cure that breach within sixty (60)
days after receiving written notice thereof, the other party may terminate this
Agreement immediately upon written notice to the other party.

      12.4  Effect of Termination.

                                       20
<PAGE>
            (a) Survival. The following provisions shall survive the expiration
or termination of this Agreement: Articles 1, 8, 9, 13 and 14, and Sections 5.2
(only with respect to COMPANY's obligation to provide final report and payment),
5.4, 5.5, 11.1, 11.2 and 12.4. In addition, 7.4 and 7.5 shall survive, but only
upon the expiration of the TERM.

            (b) Inventory. Upon the early termination of this Agreement, COMPANY
and its AFFILIATES and SUBLICENSEES may complete and sell any work-in-progress
and inventory of LICENSED PRODUCTS that exist as of the effective date of
termination, provided that (i) COMPANY pays M.I.T. the applicable running
royalty or other amounts due on such sales of LICENSED PRODUCTS in accordance
with the terms and conditions of this Agreement, and (ii) COMPANY and its
AFFILIATES and SUBLICENSEES shall complete and sell all work-in-progress and
inventory of LICENSED PRODUCTS within six (6) months after the effective date of
termination.

            (c) Destruction of TANGIBLE PROPERTY. Upon termination, COMPANY, its
AFFILIATES and SUBLICENSEES shall return or destroy the TANGIBLE PROPERTY. This
destruction shall be confirmed in writing.

            (d) Pre-termination Obligations. In no event shall termination of
this Agreement release COMPANY, AFFILIATES, or SUBLICENSEES from the obligation
to pay any amounts that became due on or before the effective date of
termination.

                             13. DISPUTE RESOLUTION.

      13.1 Mandatory Procedures. The parties agree that any dispute arising out
of or relating to this Agreement shall be resolved solely by means of the
procedures set forth in this Article, and that such procedures constitute
legally binding obligations that are an essential provision of this Agreement.
If either party fails to observe the procedures of this Article, as may be
modified by their written agreement, the other party may bring an action for
specific performance of these procedures in any court of competent jurisdiction.

      13.2 Equitable Remedies. Although the procedures specified in this Article
are the sole and exclusive procedures for the resolution of disputes arising out
of or relating to this Agreement, either party may seek a preliminary injunction
or other provisional equitable relief in any court of competent jurisdiction if,
in its reasonable judgment, such action is necessary to avoid irreparable harm
to itself or to preserve its rights under this Agreement.

      13.3  Dispute Resolution Procedures.

            (a) Mediation. In the event any dispute arising out of or relating
to this Agreement remains unresolved within sixty (60) days from the date the
affected party informed the other party of such dispute, either party may
initiate mediation upon written notice to the other party ("Notice Date"),
whereupon both parties shall be obligated to engage in a mediation proceeding
under the then current Center for Public Resources ("CPR") Model Procedure for
Mediation of Business Disputes (http://www.cpradr.org), except that specific
provisions of this Article shall override inconsistent provisions of the CPR
Model Procedure. The mediator will be selected from the CPR Panels of Neutrals.
If the parties cannot agree upon the selection of a

                                       21
<PAGE>
mediator within fifteen (15) business days after the Notice Date, then upon the
request of either party, the CPR shall appoint the mediator. The parties shall
attempt to resolve the dispute through mediation until the first of the
following occurs: (i) the parties reach a written settlement; (ii) the mediator
notifies the parties in writing that they have reached an impasse; (iii) the
parties agree in writing that they have reached an impasse; or (iv) the parties
have not reached a settlement within sixty (60) days after the Notice Date.

            (b) Trial Without Jury. If the parties fail to resolve the dispute
through mediation, or if neither party elects to initiate mediation, each party
shall have the right to pursue any other remedies legally available to resolve
the dispute, provided, however, that the parties expressly waive any right to a
jury trial in any legal proceeding under this Article.

      13.4 Performance to Continue. Each party shall continue to perform its
undisputed obligations under this Agreement pending final resolution of any
dispute arising out of or relating to this Agreement; provided, however, that a
party may suspend performance of its undisputed obligations during any period in
which the other party fails or refuses to perform its undisputed obligations.
Nothing in this Article is intended to relieve COMPANY from its obligation to
make undisputed payments pursuant to Articles 4 and 6 of this Agreement.

      13.5 Statute of Limitations. The parties agree that all applicable
statutes of limitation and time-based defenses (such as estoppel and laches)
shall be tolled while the procedures set forth in Sections 13.3(a) are pending.
The parties shall cooperate in taking any actions necessary to achieve this
result.

                               14. MISCELLANEOUS.

      14.1 Notice. Any notices required or permitted under this Agreement shall
be in writing, shall specifically refer to this Agreement, and shall be sent by
hand, recognized national overnight courier, confirmed facsimile transmission,
confirmed electronic mail, or registered or certified mail, postage prepaid,
return receipt requested, to the following addresses or facsimile numbers of the
parties:

      If to M.I.T.:     Technology Licensing Office, Room NE25-230
                        Massachusetts Institute of Technology
                        77 Massachusetts Avenue
                        Cambridge, MA  02139-4307
                        Attention:  Director
                        Tel:  617-253-6966
                        Fax:  617-258-6790

      If to COMPANY:    ViaCell Neuroscience, Inc.
                        One Innovation Drive
                        Worcester, MA 01605
                        Attention: Director, Business Development
                        Tel:  508-793-1566, Extension: 6115
                        Fax:  508-754-1289

      With a copy to:   Head, Neuroscience Division

                                       22
<PAGE>
                        Tel: 508-793-1566, Extension: 6186
                        Fax: 508-754-1289

            All notices under this Agreement shall be deemed effective upon
receipt. A party may change its contact information immediately upon written
notice to the other party in the manner provided in this Section.

      14.2 Governing Law. This Agreement and all disputes arising out of or
related to this Agreement, or the performance, enforcement, breach or
termination hereof, and any remedies relating thereto, shall be construed,
governed, interpreted and applied in accordance with the laws of the
Commonwealth of Massachusetts, U.S.A., without regard to conflict of laws
principles, except that questions affecting the construction and effect of any
patent shall be determined by the law of the country in which the patent shall
have been granted.

      14.3 Force Majeure. Neither party will be responsible for delays resulting
from causes beyond the reasonable control of such party, including without
limitation fire, explosion, flood, war, strike, or riot, provided that the
nonperforming party uses commercially reasonable efforts to avoid or remove such
causes of nonperformance and continues performance under this Agreement with
reasonable dispatch whenever such causes are removed.

      14.4 Amendment and Waiver. This Agreement may be amended, supplemented, or
otherwise modified only by means of a written instrument signed by both parties.
Any waiver of any rights or failure to act in a specific instance shall relate
only to such instance and shall not be construed as an agreement to waive any
rights or fail to act in any other instance, whether or not similar.

      14.5 Severability. In the event that any provision of this Agreement shall
be held invalid or unenforceable for any reason, such invalidity or
unenforceability shall not affect any other provision of this Agreement, and the
parties shall negotiate in good faith to modify the Agreement to preserve (to
the extent possible) their original intent. If the parties fail to reach a
modified agreement within thirty (30) days after the relevant provision is held
invalid or unenforceable, then the dispute shall be resolved in accordance with
the procedures set forth in Article 13. While the dispute is pending resolution,
this Agreement shall be construed as if such provision were deleted by agreement
of the parties.

      14.6 Binding Effect. This Agreement shall be binding upon and inure to the
benefit of the parties and their respective permitted successors and assigns.

      14.7 Headings. All headings are for convenience only and shall not affect
the meaning of any provision of this Agreement.

      14.8 Entire Agreement. This Agreement constitutes the entire agreement
between the parties with respect to its subject matter and supersedes all prior
agreements or understandings between the parties relating to its subject matter.

      IN WITNESS WHEREOF, the parties have caused this Agreement to be executed
by their duly authorized representatives.

                                       23
<PAGE>
THE EFFECTIVE DATE OF THIS AGREEMENT IS AUGUST 7, 2002.

MASSACHUSETTS INSTITUTE OF                     VIACELL NEUROSCIENCE, INC
TECHNOLOGY

By: /s/Lita L.Nelsen                           By: /s/ Seth Franklestein
    ---------------------------------------        -----------------------------
Name:  Lita L. Nelsen, Director                Name:  Seth Franklestein
       ------------------------------------           --------------------------
Title: Director Technology Licensing Office    Title: Head, ViaCell Neuroscience
       ------------------------------------           --------------------------

                                       24
<PAGE>
APPENDIX A

                     List of Patent Applications and Patents

I.    United States Patents and Applications

      M.I.T. Case No. 9265
      "A Novel Fibroblast Growth Factor Dimer"
      by Chi-pong Kwan, Rahul Raman, Ram Sasisekharan, Zachary Shriver,
      and Ganesh Venkataraman

[**]

II.   International (non-U.S.) Patents and Applications

      M.I.T. Case No. 9265
      "A Novel Fibroblast Growth Factor Dimer"
      by Chi-pong Kwan, Rahul Raman, Ram Sasisekharan, Zachary Shriver,
      and Ganesh Venkataraman

[**]

                                       25
<PAGE>
                                   APPENDIX B
           List of Countries (excluding United States) for which
    PATENT RIGHTS Applications Will Be Filed, Prosecuted and Maintained

                             EPO, Japan, and Canada

                                       26
<PAGE>
                                   APPENDIX C

                                TANGIBLE PROPERTY

[**]

                                       27

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00064-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00064-of-00352.parquet"}]]